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I  Foreword
I have the honour of presenting the 23rd General Report of Activities of the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), which 
provides an overview of its achievements in 2017.
The EMCDDA has continued to support evidence-informed drug policymaking in 
Europe, and its work is reflected in the current EU drug action plan for the period 
2017-20.
The Management Board adopted the EMCDDA’s Strategy 2025 in December 2016. 
It outlines the Centre’s strategic vision to contribute to a healthier and to a more 
secure Europe by providing sound evidence for policies and actions on drugs.
During the first year of the implementation of the Strategy, the agency successfully 
fulfilled its mission to inform sound decisions in the field of drugs at the levels 
of the EU and the Member States. As an example of its core activity, the annual 
overview of the European drug situation, the European Drug Report package, 
was launched in Brussels in June 2017. It was complemented for the first time 
by Country Drug Reports presenting summaries of the national drug situation in 
30 countries. The EMCDDA also published the first edition of a European guide 
to health and social responses to drug problems, during the Second European 
conference on addictive behaviours and dependencies in Lisbon. Finally, the 
EMCDDA and Europol launched a joint publication in November, which presents 
the latest understanding of how darknet markets function, the threats they pose to 
health and security and how Europe can respond.
A key legislative development at EU level was the adoption of a new Regulation 
on new psychoactive substances by the European Parliament and the Council in 
November 2017. I believe that this represents a great opportunity to strengthen 
the EU Early Warning System and risk assessment process and the EMCDDA’s 
leading role in monitoring new psychoactive substances over the coming years.
My special thanks go to the members of the Scientific Committee for their 
valuable contribution to the work of the EMCDDA.
I would also like to express my gratitude to the Director and all the staff of the 
agency, as well as the Heads of the Reitox national focal points and all their staff, 
for the progress achieved by the agency in 2017, as set out in this review. 
Laura d’Arrigo 
Chair of the EMCDDA Management Board
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 Introduction
I can describe this first year of implementation of our Strategy 2025 as one of the 
most productive periods for our core business, a year of enhanced partnership 
and a time of profound organisational change. 
We launched new resources for drug policy and practice, including a few 
major reports and a new series of country drug reports. A record number of 
risk assessment reports were submitted to the EU policymakers, based on the 
intensive work to implement the EU Early Warning System on new drugs, which 
we undertook for another year in close collaboration with our partners. 
New threat assessments and strategic analyses were fed by our state-of-the art 
European drug monitoring system, which continued to be enriched this year with 
novel sources of information, such as darknet markets.
Work was also nurtured by our partnerships. The year saw the adoption of the 
Reitox Development Framework, which will ensure that the EMCDDA and its main 
partners in the Member States have strategic priorities which are aligned, and 
they all contribute to the shared vision of a healthier and a more secure Europe 
by 2025. An EMCDDA Framework on International Cooperation was also adopted 
and this will guide our work towards a Europe with stronger cross-border security 
and enhanced cooperation and exchange with its non-EU partners. 
Finally, 2017 has brought us some important organisational transformations, 
which aimed to ensure that the right conditions are in place for us to be more 
effective in fulfilling our objectives and more efficient in delivering our results. 
These transformations encompassed internal restructuring and redefinition of 
roles and functions, but, most importantly, a necessary cultural change exercise. 
Together with other future measures to improve our organisational design and 
functioning, these will, I am confident, ensure the sustainability of the EMCDDA 
as an EU agency, and its long-term success in pursuing its ambitious vision and 
achieving its strategic goals, as set up by the Strategy 2025.
At the end of this crucial year in the life of the EMCDDA, on behalf of my staff and 
myself, I would like to thank our Management Board and our Scientific Committee 
for their ongoing guidance and support, the Reitox network of national focal points 
and our other EU and international partners for their valuable contribution to our 
work. 
Alexis Goosdeel 
Director
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 List of acronyms and abbreviations
ABAC electronic management and accounting system 
BCP Business continuity plan
BPP Best practice portal
CADAP Central Asia Drug Action Programme
CC candidate country
CDR Country Drug Report
CEPOL EU Agency for Law Enforcement Training
CONT Committee on Budgetary Control 
COPOLAD Cooperation Programme between Latin America and the European Union on Drugs Policies
COSI Standing Committee on Operational Cooperation on Internal Security
COSO Committee of Sponsoring Organizations of the Treadway Commission
DG Directorate-General 
DG SANTE Directorate-General for Health and Food Safety
DRD drug-related deaths 
DRID drug-related infectious diseases 
EASO European Asylum Support Office
EC European Commission
ECA European Court of Auditors
ECDC European Centre for Disease Prevention and Control
ECDD Expert Committee on Drug Dependence
EDND European Database on New Drugs
EDR European Drug Report
EDSS European drugs summer school
EFSA European Food Safety Agency
EFSQ European Facility Survey Questionnaire
EIGE European Institute for Gender Equality 
ELDD European Legal Database on Drugs
EMA European Medicines Agency
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
EMPACT European Multidisciplinary Platform Against Criminal Threats
EMQ European Model Questionnaire
EMSA European Maritime Safety Agency
ENFSI European Network of Forensic Science Institutes
ENP European Neighbourhood Policy
ENVI Committee on the Environment, Public Health and Food Safety
EP European Parliament
EQDP European Questionnaire on Drug Use among Prisoners
ERICES European Reporting on Illicit Cocaine Extraction-Conversion Sites
ESPAD European School Survey Project on Alcohol and Other Drugs
EU European Union
EU-ANSA EU Agencies Network on Scientific Advice
Euro-DEN Plus European Drug Emergencies Network
Eurojust European Union’s Judicial Cooperation Unit
eu-LISA European Agency for the operational management of large-scale IT systems in the area of 
freedom, security and justice
EWS Early Warning System
FOPH Federal Office of Public Health of Switzerland
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FRA EU Agency for Fundamental Rights
Frontex European Border and Coast Guard Agency
GPS general population survey
HCV Hepatitis C virus
HDG Horizontal Working Party on Drugs
HEA Public health unit
HFP Head of national focal point
HIPP WHO Health in Prisons Programme 
HIV Human immunodeficiency virus
HNT Healthy Nightlife Toolbox
IAS Internal Audit Service of the European Commission
ICS Internal Control Standards
ICT Information and communication technology
IPA Instrument for Pre-Accession Assistance
ISCTE-IUL ISCTE — University Institute of Lisbon
ISSDP Annual Conference of the International Society for the Study of Drug Policy
IT information technology
ICS Internal Control Standards 
ICT information and communication technology
JHA Justice and Home Affairs
KI key epidemiological indicator
KPI key performance indicator
LIBE Committee on Civil Liberties, Justice and Home Affairs
MEP Member of the European Parliament
MILDECA Mission interministérielle de lutte contre les drogues et les conduites addictives
MIS Management Information System
NAPO Network of Agencies Procurement Officers 
NEWS Early Warning System at national level
NFP national focal point
NIDA US National Institute on Drug Abuse 
NPS new psychoactive substances
OAP operational action plan
OSI open source information
PCC potential candidate country
PD Programming Document
PDU problem drug use
PhV pharmacovigilance
PM² Project Management Squared
POS Support to policy 
PRS Support to practice
SCORE Sewage analysis CORe group — Europe 
SAS Risks to public safety and security unit
SPD single programming document
SQ Structured Questionnaire
TAS Trends and analysis
TDI treatment demand indicator
UNODC United Nations Office on Drugs and Crime
UPC Universal Prevention Curriculum
UPC-Adapt UPC adapted to European needs and standards
WHO World Health Organization
Xchange online registry of evidence-based prevention programmes 
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 CHAPTER 1
 Executive summary
This report presents the implementation of the activities of the 
European Monitoring Centre for Drugs and Drug Addiction’s 
(EMCDDA’s) work programme for 2017, the first year of the 
multi-annual Programming Document (PD) 2017-19. 
I  EMCDDA publications
The most tangible results of the agency's work are its 
publications, some of which are produced in cooperation with 
partners. In 2017, 64 scientific and corporate publications, in 
addition to 30 Country Drug Reports (CDRs), were released by 
the EMCDDA. 
There were two flagship publications in 2017: the European 
Drug Report: Trends and Developments (EDR) and its 
accompanying information package, and the first edition of 
Health and Social Responses to Drug Problems: A European 
Guide (the European Responses Guide).
For the first time, 30 CDRs complemented the 2017 EDR. 
Presenting summaries of national drug situations  
(EU 28, Turkey and Norway), the CDRs were developed by the 
EMCDDA in cooperation with the Reitox national focal  
points (NFPs).
Another important output was the joint EMCDDA-Europol 
report Drugs and the Darknet, which was launched on 28 
November in Lisbon at a press conference held in the margins 
of the Heads of EU Justice and Home Affairs (JHA) agencies 
network meeting (see section on Working in partnership).
Examples of other resources include a state-of-the-art review 
on drug treatment expenditure; papers on EU policies and 
measures for drug supply reduction, and on drug squads; 
reports on cannabis legislation and on national drug trafficking 
laws and their application in the EU Member States of the 
European Union; and web topic pages on harm reduction, 
prevention, prisons and treatment.
Joint publications were also launched with the European 
Centre for Disease Prevention and Control (ECDC), on 
reducing communicable diseases in prison; and with the 
Pompidou Group, on public expenditure on supply reduction 
policies, and on costs and unintended consequences of drug 
control policies.
Twenty scientific articles or book chapters authored or  
co-authored by EMCDDA staff were also published during the 
year, enhancing the agency’s scientific reputation.
I Services to policy and practice
The EMCDDA also provided services to its customers  
(i.e. the primary beneficiaries of the agency’s work: 
policymakers within the EU institutions — the European 
Parliament (EP), the Council of the EU and the EC — and the 
EU Member States, and practitioners in the drugs field) by 
contributing to major EU drug policy documents, providing 
direct input or technical support to EU institutions (e.g. through 
briefing notes, presentations or interventions on emerging, 
high-interest drug issues, or on activities with third countries) 
and participating actively in key drug policy and practice events 
held during the year. EMCDDA staff attended some 53 key EU/
international policy events and overall contributed to nearly 
275 drug-related scientific, policy and practice events  
(see Annex 5). 
Throughout the year, the EMCDDA also maintained 
communication with the Member States. The Director paid 
high-level institutional visits to four Member States, and 
EMCDDA staff visited eight countries to support the national 
launches of the 2017 EDR. Further country visits were carried 
out at the invitation of national authorities to support different 
drug initiatives.
Furthermore, the EMCDDA’s cannabis policy news service, 
which was launched in 2016, continued to provide regular 
alerts to its policy audience. In addition, a new EMCDDA 
resource, aimed at supporting drug policy evaluation, was 
launched in October. 
General Report of Activities 2017 Chapter 1 I Executive summary
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I Best practice, training and capacity  building
Disseminating best practice, training and capacity-building 
activities were other means used by the EMCDDA to share 
knowledge in 2017.
To that end, the EMCDDA’s Best practice portal (BPP) was 
revamped in the context of the launch of the European 
Responses Guide and to make it even more practice oriented 
through the addition of the following new elements: the online 
registry of evidence-based prevention programmes (Xchange); 
the Evidence database, including systematic reviews and 
regular updates; the Healthy Nightlife Toolbox (HNT); and the 
policy and practice briefings.
For implementing training and capacity building for drug 
monitoring in Member States and partner third countries, the 
main EMCDDA vehicle remained the Reitox Academies. During 
the year, around 100 professionals were trained as part of the 
five academies organised or supported by the EMCDDA.
Another training event was the sixth European drugs summer 
school, ‘Illicit drugs in Europe: demand, supply and public 
policies’, which was organised in Lisbon in partnership with 
ISCTE — University Institute of Lisbon (ISCTE-IUL) for a record 
number of 51 students with diverse backgrounds, from 25 
countries.
The EMCDDA also enhanced its contribution to the European 
training programme for law enforcement professionals 
implemented by the EU Agency for Law Enforcement Training 
(CEPOL). As part of the tasks assigned to it within the 
operational action plans of the EU Policy Cycle on Serious 
and Organised International Crime of the Council of the EU’s 
Standing Committee on Operational Cooperation and Internal 
Security (COSI), in 2017 the EMCDDA contributed to the 
training of some 320 law enforcement professionals.
In addition, leading international experts in the field of 
addiction science met in Lisbon from 24 to 26 October for 
the Second European conference on addictive behaviours 
and dependencies (Lisbon Addictions 2017), which was 
co-organised by the EMCDDA. More than 1 200 participants — 
researchers, practitioners and policy experts from over  
70 countries — attended the high-level event.
I Digital communication
As an information agency, the EMCDDA closely follows the 
developments in the fast-moving communication field. The 
EMCDDA website has become the favoured vehicle for 
disseminating knowledge, with more than one million visitors 
registered in 2017. In addition, videos published by the 
EMCDDA on YouTube received around 190 000 views during 
the year, twice as many as in 2016.
Furthermore, 49 digital campaigns were launched and 
resulting in over 83 000 individual emails to subscribers. 
A record 18 news releases were produced in 2017, as well as 
12 factsheets and 10 news items.
I New psychoactive substances and  emerging trends
In 2017, the EMCDDA carried on playing a leading role in 
ensuring the continuous and robust implementation of the  
EU Early Warning System (EWS) on new psychoactive 
substances (NPS) under the terms of Council Decision 
2005/387/JHA on the information exchange, risk assessment 
and control of NPS (hereafter referred to as ‘the Council 
Decision’). Within this legal framework, 53 NPS were formally 
notified for the first time, bringing the total number of NPS 
currently monitored to more than 670. 
Furthermore, during the year the EMCDDA produced the 
highest number of outputs since the Council Decision entered 
into force in 2005. This reflects the significant investment 
of work required by this dynamic area. The outputs included 
ten EMCDDA-Europol Joint Reports on NPS, which were 
prepared and submitted to the EU institutions before the 
legal deadlines, and published. Furthermore, the EMCDDA’s 
Extended Scientific Committee carried out risk assessments 
of nine substances and the risk assessment reports were 
subsequently submitted to EU institutions, as stipulated by the 
Council Decision, and published.
As proposed by the European Commission (EC), based on 
the risk assessment reports submitted by the EMCDDA, 
the Council decided in 2017 that acryloylfentanyl and 
furanylfentanyl should be subject to control measures across 
Member States. This is the ultimate EU policy response to 
the NPS phenomenon and it shows that the agency has had 
significant input into EU policymaking.
General Report of Activities 2017 Chapter 1 I Executive summary
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A key development in this area was the adoption of new NPS 
legislation. This came into force on 22 November and it will 
start being applied from 23 November 2018. The legislation 
includes a stronger EWS and a faster risk assessment process, 
in which the EMCDDA will continue to play a leading role.
In addition to implementing the EWS, a key task was to monitor 
new trends in the drug phenomenon. A trendspotter report on 
high-risk drug use and NPS was published. Based on this, a 
trendspotter study on NPS use in prison was launched later in 
the year.
Leading European and international experts gathered at 
‘Testing the waters 2017’, the Third international conference 
on wastewater analysis. It was organised by the Sewage 
analysis CORe group — Europe (SCORE) and the EMCDDA, 
and took place from 26 to 27 October in the margins of Lisbon 
Addictions.
Furthermore, the EMCDDA welcomed more than 600 visitors 
to its headquarters in Lisbon In 2017.
I Working in partnership
In fulfilling its tasks, the agency relies on a large number of 
partners and, in particular, the Reitox NFPs. They play a critical 
role in providing national data from the 30 countries that report 
to the EMCDDA, namely the 28 EU Member States, Norway 
and Turkey. In November 2017, the Heads of NFPs meeting 
adopted the Reitox Development Framework. The document, 
which was prepared by a joint working group composed of 
representatives of the EMCDDA and of the NFPs, defines 
the main priorities for the network, in line with the EMCDDA 
Strategy 2025.
In performing its work and achieving its objectives, the 
EMCDDA also relies on its other EU and international partners. 
In 2017 the EMCDDA chaired the Justice and Home Affairs 
(JHA) agencies network (4). The theme chosen for the 2017 
mandate was the internet. Within this framework, a conference 
was organised in April on ‘The internet for criminal purposes: 
challenges and opportunities for the work of the JHA agencies’, 
to look at how cyberspace has influenced criminal activities 
and to explore future issues such as monitoring drug supply on 
darknet markets. 
Two other major events were organised jointly with partners in 
the harm reduction area: ‘Hepatitis week’ with ECDC  
(Lisbon, 12-16 June) and the ‘EMCDDA/WHO Health in 
(1) The following agencies are part of the JHA network: CEPOL, EASO, EIGE, 
EMCDDA, eu-LISA, Eurojust, Europol, Frontex, FRA. 
Prisons Programme (HIPP)’ conference (Lisbon,  
11-12 December). 
In December 2017, the EMCDDA Management Board adopted 
the ‘EMCDDA International Cooperation Framework 2018-25: 
maximising value from cooperation with third countries and 
international organisations towards a healthier and a more 
secure Europe’. The document updates the EMCDDA Strategy 
on International Cooperation adopted in 2007 and aims to fully 
align the activities of the agency in this area with the EMCDDA 
Strategy 2025. 
In terms of cooperation with third countries, the agency 
continued to implement the Instrument for Pre-Accession 
Assistance (IPA) projects. To that end, the IPA 5 project, which 
started in 2015 with the objective of further building the 
capacity for drug monitoring in six candidate and potential 
candidate countries (Albania, Bosnia and Herzegovina, 
the former Yugoslav Republic of Macedonia, Kosovo (5), 
Montenegro and Serbia), was successfully completed, and a 
new project, IPA 6, was initiated for the same countries, to run 
until 30 June 2019.
Finally, the EMCDDA and the Federal Office of Public Health 
of Switzerland (FOPH) signed a Working Arrangement on 
12 September 2017. The signatories were Alexis Goosdeel, 
EMCDDA Director, and Pascal Strupler, Director of FOPH.
I Corporate developments
The agency’s Management Board adopted the EMCDDA 
Strategy 2025 in December 2016, and 2017 was the first 
year under it. At organisational level, the focus was therefore 
placed on designing and implementing a corporate change 
management programme encompassing the measures 
necessary for a smooth and coherent transition towards 
the new long-term strategic framework of the agency. 
The two main elements of that were the refinement and 
implementation of the new organisational structure adopted by 
the Management Board in December 2016; and the alignment 
of the EMCDDA’s forthcoming PD, for 2019-21, with the 
strategy. 
During the year, the agency performed well both operationally 
and financially. This was confirmed by the high level of 
implementation of the 2017 work programme, as well as by 
the yearly budget execution rate, which reached 100 % for 
commitment appropriations.
(2) This designation is without prejudice to positions on status, and is in line with 
UNSCR 1244/99 and the ICJ Opinion on the Kosovo declaration of independence. 
It applies to all mentions of Kosovo in this report and its annexes
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 CHAPTER 2
  Core business: monitoring  
and reporting on the drugs problem
I Communicating evidence and knowledge  exchange (Key area 1) 
The ultimate purpose of the work performed by the EMCDDA 
is to inform sound decisions in the field of drugs at the 
levels of the EU and its Member States. The results of the 
data collection, monitoring and analysis process provide the 
evidence that policymakers and professionals from across the 
EU need in order to tackle the drug phenomenon effectively.
This evidence is communicated by the EMCDDA through 
various means, depending on the needs of its audiences/
customers. The most important means are the outputs ― 
products and services ― that the agency provides to its 
customers (see Figure 1). These outputs are complemented by 
a range of knowledge-exchange activities, which include the 
dissemination of best practice as well as capacity-building and 
training initiatives.
I Products
In 2017, the EMCDDA launched 64 scientific and corporate 
publications and 30 Country Drug Reports (CDRs). In addition, 
EMCDDA staff authored or co-authored 20 scientific articles or 
book chapters.
Two of these outputs were flagship EMCDDA publications, 
namely the 2017 European Drug Report: Trends and 
Developments (EDR), and its acompanying information 
package, and the first edition of Health and Social Responses 
to Drug Problems: A European Guide (the European 
Responses Guide).
The 2017 European Drug Report package
On 6 June 2017, the EMCDDA presented its annual analysis of 
the drug problem in Europe: the EDR package, an interactive 
and interlinked annual update on the latest trends in drug 
supply and drug use, and the associated health and social 
responses in Europe.
In print and online in 24 languages, this multilingual, 
multimedia package offers easy access to evidence-based 
information on drugs for the 28 EU Member States, Turkey and 
Norway.
The report was launched at a press conference in Brussels, by 
Dimitris Avramopoulos, European Commissioner for Migration, 
Home Affairs and Citizenship, Laura d’Arrigo, Chair of the 
EMCDDA Management Board, and Alexis Goosdeel, EMCDDA 
Director. Furthermore, the EMCDDA participated in national 
EDR launches held in seven EU Member States (Cyprus, Latvia, 
Lithuania, Poland, Romania, Slovenia, Slovakia) and Norway.
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FIGURE 1. Key facts and figures
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The 2017 EDR was complemented for the first time by  
30 CDRs (see Figure 3), presenting summaries of national 
drug situations in the 28 EU Member States, Turkey and 
Norway. Developed by the EMCDDA in cooperation with the 
Reitox NFPs, these graphic-rich reports cover drug use and 
public health problems; drug policy and responses; and drug 
supply. 
The Statistical Bulletin completed the picture by providing 
access to the quantitative data used by the EMCDDA for 
reporting on the drug situation. 
Also published on the day of the 2017 EDR launch were: 
  High-risk drug use and new psychoactive substances
  updates on preventing overdose deaths, changes in  
Europe’s cannabis resin market, drug consumption 
rooms, synthetic cannabinoids and wastewater-based 
epidemiology (Perspectives on drugs).
A motion graphic, two news releases in 24 languages (taster, 
highlights), a special edition of the newsletter Drugnet Europe 
(issue 98) and a promotional brochure were produced by the 
agency to mark the launch of the EDR.
FIGURE 2. Example of a visual used on social media to promote the European Drug Report 2017
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FIGURE 3. Country Drug Reports
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First European guide on responding to drug problems 
This new EMCDDA flagship publication aims to provide  
a state-of-the-art overview of the responses to drug use 
across the EU and their effectiveness, as well as implications 
for action. The report complements the annual EDR and 
the triennial EU Drug Markets Report. Together, these three 
reports aim to provide a comprehensive European picture 
to assist policymakers and practitioners to develop policies 
and interventions that will contribute to a healthier and more 
secure Europe.
The guide views health and social responses to drug problems 
from the three perspectives of responding to:
  problems associated with different types of drug and 
patterns of use;
  the needs of different groups (e.g. women, young people, 
migrants, ageing drug users); and
  problems in different settings (e.g. prisons, nightlife, 
festivals, schools, workplaces, local communities).
Designed as an initial reference point, the publication includes 
summaries and user-friendly signposting to highlight key 
information, best practice examples, and implications for 
policy and practice. The guide links to the EMCDDA Best 
practice portal (BPP), which contains a wide range of 
resources, including the ‘Xchange’ registry of evidence-based 
programmes, and standards to boost the quality of responses. 
Two news releases in 24 languages provide further details 
(taster, highlights).
Drugs and the darknet: joint EMCDDA-Europol report
On 28 November, the EMCDDA and Europol launched a 
joint report on Drugs and the darknet. To that end, a press 
conference — in the presence of European Commissioner 
Avramopoulos and the two agency directors — was held in the 
margins of the Heads of EU JHA agencies network meeting, 
which was organised under the EMCDDA’s 2017 chairing of 
the JHA agencies network (see Cross-cutting area C).
The report presents the latest understanding of how darknet 
markets function, the threats they pose to health and security, 
and how Europe can respond. Two motion graphics on 
‘Cryptocurrencies in the darknet’ and ‘Darknet markets 
ecosystem’ were developed specifically for this report. A joint 
news release was issued by the EMCDDA and Europol.
Other joint publications 
In November 2017 the EMCDDA released a joint systematic 
review with ECDC on whether or not active case finding can 
help reduce communicable diseases in prisons. The findings 
from this systematic review will serve as the evidence base 
for the development of ECDC and EMCDDA public health 
guidance on active case finding for communicable diseases in 
prison settings, to be released in 2018.
A joint publication was released with the Pompidou Group on 
Public expenditure on supply reduction policies. 
The EMCDDA’s new flagship publication, the European guide on responding 
to drug problems. 
© EMCDDA, Silke Vitt
Drugs and the darknet press conference on 28 November in Lisbon. 
From left to right: Rob Wainwright, Europol Executive Director; Dimitris 
Avramopoulos, European Commissioner for Migration, Home Affairs and 
Citizenship; Alexis Goosdeel, EMCDDA Director; Kathryn Robertson, Head 
of Media relations and marketing, EMCDDA.
© EMCDDA, Nuno Saraiva  
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Threat assessment reports
In 2017, the EMCDDA published the highest number of 
outputs related to the implementation of Council Decision 
2005/387/JHA on the information exchange, risk assessment 
and control of new psychoactive substances (see Key area 2) 
since the entering into force of this Decision in 2005.  
Nine EMCDDA-Europol Joint Reports on new psychoactive 
substances (NPS) (see Figure 4 for details) and three risk 
assessment reports were published in the EMCDDA layout. 
Furthermore, as part of the EU Policy Cycle on Serious and 
Organised International Crime of the COSI, work on two 
Europol-EMCDDA threat assessments (on methamphetamine 
and on new synthetic opioids) was carried out and the reports 
will be publicly available in 2018. 
In the same category of threat assessment reports, the 
trendspotter report High-risk drug use and new psychoactive 
substances was also published. This report provides a first look 
at the emergence of more problem forms of use of NPS among 
a range of demographic groups, including people who inject 
opioids and amphetamines, prisoners, homeless people and 
men who have sex with men.
Topic overviews and updates on important  
drug-related issues
In the course of 2017, the EMCDDA also released various 
papers, technical reports and manuals on topics relevant to 
policymakers and practitioners. 
As an example, the costs related to drug treatment were 
spotlighted in an EMCDDA Insights publication released in 
2017, entitled Drug treatment expenditure: a methodological 
overview. 
It is estimated that over one million people receive treatment 
for drug-related problems in the European Union every year. 
In collaboration with experts from around the globe, the 
EMCDDA compiled this analytical report, the first of its kind, 
to present the current practices used for estimating drug 
treatment costs in order to help fill the knowledge gap.
At a time of increased debate on the laws controlling the use 
of cannabis in the European Union, the EMCDDA published in 
March 2017 a report answering some of the questions most 
often asked about cannabis legislation: Cannabis legislation 
in Europe: an overview. In addition, policymakers were kept 
informed through regular alerts on new developments in the 
cannabis policy area.
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FIGURE 4. EMCDDA-Europol Joint Reports on NPS in 2017
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A technical report on national drug trafficking laws and their 
application in the EU Member States was published in January 
2017. It compares the penalties set out in national laws for 
trafficking cannabis, amphetamine, cocaine and heroin with 
the sentencing outcomes expected by the legal practitioners, 
including penalties imposed and the estimated time likely to 
be spent in prison.
Also in January, the EMCDDA published a paper on Drug 
supply reduction: an overview of EU policies and measures 
which provides an overview of EU policies and responses 
to the production and trafficking of illicit drugs within the 
international context. It considers the different strategic areas 
involved, the EU structures concerned, and some of the key 
measures currently being implemented by the EU and its 
international partners. 
In December, the EMCDDA published a paper on Developing 
drug supply monitoring in Europe: current concepts, which 
presents a snapshot of the EMCDDA’s conceptual framework 
for supply monitoring (see Key area 3).
Additionally, a paper on Drug squads: units specialised in drug 
law enforcement in Europe. Situation in the EU Member 
States, Norway and Turkey in 2015 was released by the 
EMCDDA in December.
In 2017 the agency also further developed its web resources 
and released four new topic pages (harm reduction, prevention, 
prisons and treatment). The new prison topics page, launched 
in October, provides a comprehensive overview of resources 
available on this issue.
Another topic page was dedicated to legal approaches to 
drugs and driving. This topic overview describes the national 
laws in EU Member States and Norway, along with EU 
legislation, on drugs and driving.
I Services: support to policy
EU level
In 2017, the EMCDDA continued to support drug policy 
dialogue at EU level by providing expertise and technical 
information to the EU institutions (the European Parliament 
(EP), the Council of the EU and the EC). 
With regard to collaborating with the EP, the Director 
participated in various meetings of the Committee on Civil 
Liberties, Justice and Home Affairs (LIBE).
On 9 February, the EMCDDA Director presented the priorities 
of the EMCDDA’s chairing of the network of JHA agencies in 
2017, as well as of the EMCDDA Strategy 2025 and the PD 
for 2017-19. He then presented the findings from the most 
important annual publication — the 2017 EDR — to the LIBE 
Committee in Brussels on 8 June. On 11 October, the Director 
attended a meeting of the LIBE Committee during which he 
made a presentation on the performance of the agency in 
2016, based on the final accounts and figures of the General 
Report of Activities for 2016. 
Throughout the year, the Director had also bilateral meetings 
with several Members of the European Parliament (MEPs) — 
members of the LIBE Committee and the Committee on the 
Environment, Public Health and Food Safety (ENVI) — on 
issues concerning the work of the agency.
Agency staff participated in an expert panel on ‘Public safety 
and public health: municipal drug policies in the Member 
States’, hosted by MEP Michał Boni (Poland), member of 
LIBE, and the Polish Drug Policy Network on 20 June in 
Brussels. A member of the EMCDDA staff participated in the 
MEP-Scientist Pairing Scheme 2017, under the topic ‘Science 
meets Parliament: the role of science in a post-fact society’, 
which was organised by the European Parliamentary Research 
Service from 28 to 30 November 2017 at the EP in Brussels.
FIGURE 5. Prison topic page on the EMCDDA website
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Throughout 2017 the EMCDDA also continued to contribute 
to key policy documents. To that end, the agency fulfilled the 
tasks assigned to it within the EU Agenda on Security 2015-20. 
Core tasks in this regard were to support the multi-annual EU 
Policy Cycle on Serious and Organised International Crime, 
in particular the priorities set by COSI on heroin, cocaine 
and synthetic drugs in the annual European Multidisciplinary 
Platform Against Criminal Threats (EMPACT) operational 
action plans (OAPs). This included providing training to law 
enforcement professionals (see joint activities with CEPOL in 
‘Services: support to practice’), supporting Europol on reporting 
on synthetic drugs and cocaine production sites, contributing 
to EMPACT technical meetings, providing input for the drafting 
of the next EMPACT OAPs, providing briefing notes to the EC 
on issues such as the drug situation in Afghanistan or Jordan 
and contributing to the EU’s comprehensive assessment of the 
EU Security Policy. 
A key contribution to EU policymaking is provided by the 
EMCDDA in the NPS area (see also Key area 2). To that end, 
as proposed by the EC, based on the risk assessment reports 
submitted by the EMCDDA, the Council decided in 2017 that 
acryloylfentanyl and furanylfentanyl should be subject to 
control measures across Member States. This is the ultimate 
EU policy response to the NPS phenomenon and it shows the 
agency has had significant input into EU policymaking.
In the field of HIV/AIDS, in January the EMCDDA Director 
spoke at the opening session of a two-day conference on 
HIV, co-organised by the Maltese EU Presidency and ECDC. 
The Director also gave a presentation at the Mini HCV Policy 
Summit on ‘Eliminating HCV in Portugal’, hosted by MEP 
Carlos Zorrinho (Portugal, substitute member of the ENVI 
Committee), which took place on 12 October at the EP in 
Brussels. He also participated in the Mini HCV Policy Summit 
on ‘Eliminating HCV in Greece’, hosted by MEP Georgios 
Kyrtsos (Greece, Member of the Committee on Economic and 
Monetary Affairs) on 22 November at the EP in Brussels. 
The EMCDDA also participated in and delivered presentations 
at the meetings of the HIV/AIDS, Hepatitis and Tuberculosis 
Think Tank, organised by the Directorate-General for Health 
and Food Safety (DG SANTE) and held in Luxembourg, on 21 
to 22 June and 19 December, and the meeting of the EU HIV/
AIDS, Viral Hepatitis and Tuberculosis Civil Society Forum  
(18-19 December). Throughout the year, the cooperation 
with DG SANTE was further developed. This included a 
presentation on 6 December in Luxembourg of the ´Health and 
social responses to drug problems: a European guide´ at the 
meeting of the Expert Group on Health Information delivered 
by the Director, who also met with Mr John F. Ryan, Director of 
DG SANTE.
The agency was also very active in providing support to the EC 
and the European External Action Service on activities with 
third countries. This included contributions to the EU non-
paper on drugs for Montenegro and for Serbia, to the 2018 EU 
enlargement package, and to the Mini-Dublin Group reports on 
Western Balkan and selected European Neighbourhood Policy 
countries, as well as ad hoc support to the second phase of 
the Cooperation Programme between Latin America and the 
European Union on Drugs Policies (COPOLAD II) and the 
Central Asia Drug Action Programme — Phase 5 (CADAP 5) 
projects of the EC.
The EMCDDA continued to strengthen the cooperation with 
the relevant EC services, in particular with DG HOME, the 
agency's Partner DG. Several coordination meetings took 
place with the EC during the year, and briefing notes were 
provided when requested to support missions carried out by 
EC representatives to third countries.
The agency also attended some 53 key EU and international 
drug policy meetings, including the meetings of the Horizontal 
Working Party on Drugs (HDG), which were organised 
throughout the year under the Maltese and Estonian 
Presidencies of the Council of the EU; the two national drug 
coordinators’ meetings held under the same Presidencies 
(in St Julians, Malta, on 24 April and in Tallinn on 13-14 
September); and the 60th Session of the Commission on 
Narcotic Drugs (Vienna, 13-15 March). 
There were several high-level visits from EU institution 
representatives to the EMCDDA in 2017. Highlights included 
the visits of:
  Gilles de Kerchove, EU Counter-Terrorism Coordinator  
(12 January);
  Carlos Moedas, European Commissioner for Research, 
Science and Innovation (8 May);
  Julian King, European Commissioner for Security Union  
(6 November);
  João Gomes Cravinho, Head of the EU Delegation in Brazil 
(19 December).
In the drug research area, the EMCDDA, at the request of 
DG Migration and Home Affairs, became a member of the 
evaluation committee in charge of assessing the proposals 
submitted under the ‘Supporting Initiatives in the Field of 
Drugs Policy’ 2017 call. Furthermore, the agency supported its 
Scientific Committee in preparing and delivering to the HDG its 
input to the Annual Dialogue on Research priorities. 
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Last but not least, the EMCDDA’s cannabis policy news service, 
which was launched in 2016, continued to provide regular 
alerts to its subscribers (a total of 161 by the end of 2017).
Member States
Throughout the year, the EMCDDA maintained communication 
with the Member States, in particular with the agency’s main 
national partners and data providers, the Reitox NFPs.
The EMCDDA Director paid high-level institutional visits to 
Greece (21-22 September), Bulgaria (25-27 September), the 
Czech Republic (17-18 October) and Luxembourg  
(5 December). EMCDDA staff also travelled to support the 
national launches of the 2017 EDR in seven EU Member 
States (Cyprus, Latvia, Lithuania, Poland, Romania, Slovenia, 
Slovakia) and Norway. 
Further technical missions were carried out at the invitation 
of national authorities to support different countries’ drug 
initiatives. One example is the support provided to Cyprus: the 
EMCDDA participated in the drug strategy evaluation meeting 
(Nicosia, 6-7 June) and a policy evaluation seminar (Larnaca, 
14-15 November). On both occasions, key EMCDDA resources 
were presented, namely the 2017 EDR and the European 
Responses Guide. 
The EMCDDA also received visits from high-level 
representatives or ambassadors from several Member States. 
These included the visits of:
  Balázs Molnár, Deputy State Secretary, Ministry of Foreign 
Affairs, Hungary (27 January);
  Members of the European Affairs Committee, Portuguese 
National Parliament (11 July);
  Ana Paula Zacarias, Secretary of State for European 
Affairs, Portugal (22 August).
Finally, in October the EMCDDA launched its new resource 
Evaluating drug policy: a seven-step guide to support the 
commissioning and managing of evaluations. The document 
summarises the main issues concerning evaluation in the 
field of drug policy. Recognising that there is no single correct 
way to undertake an evaluation, the publication is designed to 
assist policymakers in choosing the best approach to suit their 
circumstances and to maximise the value of any evaluation.
An accompanying web page was also launched to provide 
more information and resources on policy evaluation.  
It includes information on EU drug policies as well as links to 
further resources.
I Services: support to practice
Knowledge exchange is a key task of the EMCDDA. This 
involves the dissemination of best practice and the design and 
implementation of capacity-building and training initiatives for 
different audiences.
Best practice portal
Identifying and disseminating information on the effectiveness 
of interventions across the EU and beyond is a core area for 
the EMCDDA. The main dissemination channel is the Best 
practice portal (BPP).
In 2017 the BPP was revamped in the context of the launch 
of the European Responses Guide and to make it even more 
practice oriented through the addition of the following new 
elements:
  Xchange prevention registry: online registry of evidence-
based prevention programmes. It supports decision 
making by continuously compiling information on 
implementation experiences and on the effectiveness of 
programmes.
  Evidence database: provides access to the latest evidence 
on drug-related interventions. The information is based on 
systematic reviews and is updated regularly.
  Policy and practice briefings: a one-stop-shop for anyone 
planning or delivering health and social responses to 
drug problems in Europe. Each briefing consists of a 
summary of the main issues, the main response options, 
an overview of the current situation, key implications for 
policy and practice, and links to further resources.
FIGURE 6. Best practice portal on the EMCDDA website
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Furthermore, since early 2017 the EMCDDA has been hosting 
an online Healthy Nightlife Toolbox (HNT), which collects and 
provides information on good practice interventions targeting 
drug and alcohol use and related problems among young 
people in nightlife settings. The HNT expands on the model for 
partygoers in the BPP.
In addition, the EMCDDA published in 2017 a review on 
Communities That Care and one on Drug testing in schools.
One more publication, the technical report Implementation 
of drug-, alcohol- and tobacco-related brief interventions in 
the European Union Member States, Norway and Turkey, was 
released in March 2017.
Training and capacity building
Another effective means of supporting practice is through 
training and capacity-building activities. During the 
year, several Reitox Academies, and training initiatives 
in cooperation with traditional partners, such as ISCTE — 
University Institute of Lisbon (ISCTE-IUL) and CEPOL, took 
place.
Reitox Academies
The Reitox Academies are the main capacity-building initiative 
of the EMCDDA in collaboration with, and for the benefit of, its 
partners in the Member States or third countries. Five Reitox 
Academies were organised in 2017 for 102 professionals from 
EU Member States and non-EU countries. Further details are 
presented in Key area 3 and Cross-cutting areas A and C.
European drugs summer school
The sixth European drugs summer school (EDSS), ‘Illicit drugs 
in Europe: demand, supply and public policies’, opened on 
26 June 2017 in Lisbon. The two-week course is a previously 
established joint initiative of the EMCDDA and ISCTE-IUL 
and is supported by the US National Institute on Drug Abuse 
(NIDA). 
In 2017, the EDSS reached its maximum capacity with a 
record number of 51 participants enrolled from some  
25 countries.
The EMCDDA and ISCTE-IUL will further strengthen their future 
cooperation thanks to a new Memorandum of Understanding 
signed between the two bodies on 10 May 2017 in Lisbon. 
Support for training activities organised by CEPOL
As part of its contribution to the EMPACT OAPs of the  
EU Policy Cycle on Organised and Serious International 
Crime, in 2017 the EMCDDA continued to support the 
training activities organised by CEPOL for law enforcement 
professionals. This included participation as experts in five 
training initiatives (webinars or residential) organised by this 
partner agency (see Table 1).
European drugs summer school, class of 2017
© ISCTE-IUL, Hugo Alexandre Cruz
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For the first time, in 2017 the EMCDDA developed and 
implemented, in partnership with CEPOL and the Portuguese 
Judicial Police, a three-day residential training course on ‘Drug 
markets and drug-related crime: strategic analysis’, based 
on the EU Drug Markets Report published in 2016 jointly by 
the EMCDDA and Europol. The course, which was organised 
in Lisbon, was attended by senior law enforcement officers 
from EU Member States and Switzerland. As a result of a high 
satisfaction rate among participants, a new edition of this 
course will be organised in June 2018.
Finally, in 2017 the EMCDDA continued its work on the 
development of a European training module for prevention 
professionals based on the Universal Prevention Curriculum 
(UPC). The UPC was adapted to European needs and 
standards (UPC-Adapt) through the active involvement of the 
EMCDDA. Piloting in nine EU Member States (Belgium, Czech 
Republic, Germany, Estonia, Spain, Croatia, Italy, Poland and 
Slovenia) is currently ongoing.
I Dissemination of results and evidence —   the EMCDDA’s digital channels
Online communication is the agency’s preferred channel for 
disseminating up-to-date knowledge on all facets of the drug 
problem, with the EMCDDA website at the core. Social media 
and multimedia channels are used to communicate events 
and findings and engage more actively with our audiences 
in real time. Figure 7 shows our activities through online 
communication channels.
Furthermore, the EMCDDA maintained relations with the 
media throughout the year. A total of 300 requests from the 
press were received and answered in 2017.
In the course of the year, two media-monitoring projects were 
carried out, one relating to the EDR and the other relating to 
the European Responses Guide. 
In relation to the EDR, the Kantar Media report shows a 
total of 4 683 items of coverage (36 % more than in 2016). 
International content enjoyed a third consecutive year of 
increasing volumes, rising from 971 items in 2016 to 1 242 
items in 2017, representing a 28 % increase. The United States 
accounted for 60 % of the international volume (748 items).
Concerning the European Responses Guide, 358 articles were 
published. Nearly 2 000 articles were tracked relating to the 
EMCDDA activities unfolding in Lisbon Addictions week  
(28 EU Member States, Norway, Turkey and international 
markets).
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FIGURE 7. EMCDDA online communication channels
TAbLE 1. Training initiatives organised with CEPOL in   
2017: activities and number of participants
Course Residential Webinar
Webinar: Introduction to the ERICES(*) 
tool for data collection on cocaine 
laboratories dismantled in Europe
89
Webinar: Clandestine laboratories 
producing NPS
94
Cocaine trafficking training course 38
Heroin trafficking training course 31
Drug markets and drug-related crime: 
strategic analysis
38
Illicit laboratories dismantling course 30
Grand total 137 183
Source: CEPOL. 
(*) European Reporting on Illicit Cocaine Extraction-Conversion Sites.
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Leading international experts in the field of addiction science met in Lisbon 
from 24 to 26 October for the Second European conference on addictive 
behaviours and dependencies. More than 1 200 participants attended the 
high-level event, which brought together researchers, practitioners and policy 
experts from over 70 countries. The latest scientific evidence in the area was 
discussed and challenges relating to illicit drugs, alcohol, tobacco, gambling, 
the internet and other addictive behaviours were explored. 
During the three-day conference, close to 500 presentations were delivered, 
over 200 posters exhibited and more than 20 lectures offered by internationally 
renowned researchers and professionals. 
Close to half of the conference participants responded to the online 
questionnaire and the results speak for themselves:
  More than 90 % of respondents rated the keynote speakers as ‘excellent’, 
‘very good’ or ‘good’, while the oral presentations were rated highly by 88 % 
of the respondents.
  More than 95 % of respondents rated the overall impression of the 
conference as ‘excellent’, ‘very good’ or ‘good’.
  A total of 87 % of respondents would recommend Lisbon Addictions to 
others.
The EMCDDA’s presence at Lisbon Addictions
EMCDDA staff gave 27 presentations and showcased eight posters during the 
three-day-event and chaired a number of sessions. Conference participants 
were encouraged to meet EMCDDA staff, browse through publications and 
explore the website at the joint EMCDDA-SICAD (Serviço de Intervenção 
nos Comportamentos Aditivos e nas Dependências) stand during the whole 
conference. 
In the margins of the conference, the EMCDDA partnered with key European 
and international players in the drugs field to organise a variety of additional 
events, such as the Third international conference on wastewater analysis, 
organised by the Sewage analysis CORe group — Europe (SCORE) and the 
EMCDDA, and the Third international symposium on drug-impaired driving, 
a collaborative effort by the EMCDDA, the Canadian Centre on Substance 
Use and Addiction, the NIDA international programme and the New Zealand 
Drug Foundation. With cannabis use and policy evolving internationally, drug-
impaired driving has become an increasingly important issue. This international 
symposium provided those concerned with policy developments in the field of 
cannabis with an overview of current knowledge and the latest developments in the area of cannabis-impaired driving.
Lisbon Addictions 2017
FIGURE 8. Conference banner
EMCDDA exhibition stand at Lisbon Addictions.
© EMCDDA, Nuno Saraiva
General Report of Activities 2017 Chapter 2 I Core business: monitoring and reporting on the drugs problem 
25 / 81
I Early warning and threat assessment    (Key area 2) 
I Responding to NPS ― EU Early Warning System  and risk assessment
In 2017, together with its partners in Member States 
(the Reitox network of the Early Warning System (EWS) 
correspondents), Europol and the European Medicines Agency 
(EMA), the EMCDDA carried on ensuring continuous and 
robust implementation of the EWS under the terms of Council 
Decision 2005/387/JHA on the information exchange, risk 
assessment and control of NPS. Key outputs of the EWS have 
been rapid notifications and public health alerts on NPS, the 
exchange of forensic and toxicological analytical data, and 
outputs related to the implementation of the Council Decision 
and the risk assessment mechanism.
In addition:
  Ten EMCDDA-Europol Joint Reports, namely 
on furanylfentanyl, AB-CHMINACA, ADB-
CHMINACA, 5F-MDMB-PINACA, CUMYL-4CN-
BINACA, 4-fluoroisobutyrylfentanyl (4F-iBF), 
tetrahydrofuranylfentanyl (THF-F), carfentanil, 
cyclopropylfentanyl and methoxyacetylfentanyl, were 
prepared, submitted to the EU institutions and published 
on the EMCDDA website in 2017. 
  Nine risk assessments on acryloylfentanyl, furanylfentanyl, 
AB-CHMINACA, ADB-CHMINACA, 5F-MDMB-PINACA, 
CUMYL-4CN-BINACA, 4-fluoroisobutyrylfentanyl (4F-iBF), 
tetrahydrofuranylfentanyl (THF-F) and carfentanil 
were carried out by the EMCDDA’s Extended Scientific 
Committee on 22 February, 23 May and 6-8 November, 
and the risk assessment reports were subsequently 
submitted to EU institutions as stipulated by the Council 
Decision. 
  Based on the risk assessment reports submitted by the 
EMCDDA, the Council of the EU decided on 25 September 
and 15 November respectively that acryloylfentanyl and 
furanylfentanyl should be subject to control measures 
across Member States. 
  Following the control measures, three risk assessments 
were published, on MDMB-CHMICA (this report was 
the result of a risk assessment exercise carried out by 
the extended Scientific Committee of the EMCDDA in 
July 2016), acryloylfentanyl and furanylfentanyl. They 
incorporated the Council implementing decisions on 
subjecting the substances to control measures in 2017.
Network management and the provision of technical 
assistance on a daily basis to the members of the Reitox EWS 
network continued to be central activities of the EMCDDA 
in 2017. This reflects the importance of maintaining strong 
networks to ensure that early warning activities are effective. 
Literature searches were performed for all the substances 
that were detected for the first time in Europe and formally 
notified to the EWS Network. In addition, structured data were 
collected periodically on all monitored substances, and trends 
in the NPS market were identified and analysed.
The 17th Annual Meeting of the Reitox EWS Network took 
place on 5 and 6 December, in conjunction with the closing 
meeting of the EU-funded project ‘SPICE-profiling’. All 
presentations given at this meeting and the minutes of the 
proceedings were published in the European Database on New 
Drugs (EDND).
In accordance with Article 10 of the Council Decision, the 
EMCDDA-Europol 2016 annual report on the implementation 
of Council Decision 2005/387/JHA was prepared by these two 
agencies, submitted to EU institutions in June and published 
in July 2017. The report presented the key activities performed 
by the EMCDDA and Europol in 2016, including a list of the 
NPS that were notified, the Joint Reports produced, the risk 
assessments conducted and the public health alerts issued.
Substances posing serious health risks were intensively 
monitored throughout 2017. Nine substances, AB-CHMINACA, 
ADB-CHMINACA, 5F-MDMB-PINACA, CUMYL-4CN-BINACA, 
4-fluoroisobutyrylfentanyl (4F-iBF), tetrahydrofuranylfentanyl 
(THF-F), carfentanil, cyclopropylfentanyl and 
methoxyacetylfentanyl met the criteria for launching a Joint 
Report with Europol, in accordance with Article 5 of the 
Council Decision.
More than
NPS notied for
the rst time
953
NPS currently 
monitored
670
2017 
NPS risk assessed
2
NPS subject to
control measures
across Member States
further to the decisions
made by the Council
FIGURE 9. EWS and risk assessment: key facts and figures
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To that end, ad hoc data collection activities for the preparation 
of the Joint Reports were launched. Structured data were 
requested from the Reitox NFPs, Europol, the EMA and WHO. 
In addition, a search of open source information (OSI) was 
performed and the results were collated, reviewed, validated 
and analysed.
The Joint Reports were prepared and submitted to the EU 
institutions before the required legal deadlines stipulated by 
the Council Decision.
During the course of the year, the agency was invited to 
disseminate its knowledge at various events and training 
initiatives, as well as to the large number of visitors to the 
EMCDDA. An important event was the Fifth International 
Conference on Novel Psychoactive Substances, which the 
EMCDDA co-organised. It took place in Vienna on  
23-24 October 2017. 
Information exchange with the EMA and the EU 
pharmacovigilance system on medicines and substances with 
medicinal properties was ongoing in 2017. Th e two agencies 
continued to strengthen their collaboration in accordance with 
their roles under Council Decision 2005/387/JHA, Regulation 
(EU) No 1235/2010 and the working arrangements in place. 
In recent years, there has been an increase in the number of 
medicinal products monitored by the EMCDDA under the EWS. 
In turn, this has led to an increase in the number of requests 
made by the Pharmacovigilance Risk Assessment Committee 
of the EMA to the EMCDDA for information on such medicines, 
after signals related to their misuse and abuse were identified 
by the EWS. 
The Toxicovigilance System of the EWS was further developed. 
With a view to detecting signals of NPS that pose health 
concerns, daily searches and reviews of major English-
language OSI, including scientific and medical literature, were 
performed. 
The agency also actively cooperated with international 
bodies, particularly the United Nations Office on Drugs and 
Crime (UNODC) and WHO in Geneva, in order to support 
prioritisation, scheduling discussions and information 
exchange activities and meet the need to respond at 
international level to the harms caused by NPS. A list of 
substances to assist in the prioritisation of substances to 
be reviewed during the 39th Expert Committee on Drug 
Dependence (ECDD) meeting was provided by the EMCDDA 
on 12 May. Furthermore, an expert meeting was organised 
between WHO and the EMCDDA at the EMCDDA premises, on 
the same date.
The EMCDDA and the UNODC also strengthened their 
collaboration on the collection of data related to the 
identification and seizure of NPS in Europe. This collaboration 
is based on the recognition of the world-leading role played 
by the EU EWS and the EMCDDA in the early identification of 
threats related to NPS. The list of NPS notified to the EWS was 
shared by the EMCDDA with the UNODC.
As part of the IPA 5 project (see Cross-cutting area C 
for details), support was also provided to third countries 
(candidate countries (CCs) and potential candidate countries 
(PCCs)) to design and operate an EWS at national level 
(NEWS). To that end, the exchange of communication on news 
related to NPS and EWS in Europe was ongoing between the 
EMCDDA and the beneficiaries’ representatives. 
Furthermore, representatives of four CCs and PCCs attended 
the 17th Annual Meeting of the Reitox EWS Network in 
December. Two satellite events were organised around the 
meeting: on control of NPS and on reporting of NPS. On that 
occasion, the EMCDDA presented an adapted version of 
the EU EWS formal notification, to be used by partner third 
countries starting from 2018.
An important development in this area was the adoption 
of a new NPS legislation on 24 October 2017.  
This came into force on 22 November, one day after 
its publication in the Official Journal of the European 
Union, and it will start being applied from November 
2018.
The legislation includes a stronger EWS and a faster 
risk assessment process. The developments are in 
response to the recent growth in the market in NPS and 
follow a proposal from the EC comprising:
  a Regulation regarding information exchange on, 
and an early warning system and risk assessment 
procedure for, new psychoactive substances 
(amending the EMCDDA Founding Regulation); and
  a Directive including new psychoactive substances in 
the definition of ‘drug’.
The new legislation retains the current three-step 
approach to responding to NPS — early warning, risk 
assessment and control measures — while significantly 
strengthening existing processes by streamlining 
and accelerating data collection and assessment 
procedures. Throughout the new procedure, shorter 
deadlines are introduced.
The EMCDDA will continue to play a leading role in 
monitoring NPS reported by EU Member States.
New NPS legislation adopted in 2017
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Capacity building in this area also included one regional Reitox 
Academy and three seminars for CC and PCC beneficiaries, 
which were organised by the EMCDDA with support from 
experts from Croatia, Hungary and Poland, as follows:
  Reitox Academy on ‘Methods for detection NPS and the 
role of forensic laboratories in the national early warning 
system’ (Hungary, 4-6 April), with 15 participants —  
the event, the first of this kind, was organised jointly with 
the Hungarian Institute of Forensic Sciences;
  ‘NPS for customs, courier services and the main post office’ 
(Belgrade, 28 April), with 20 participants;
  ‘NPS for representatives of health services’ (Banja Luka, 
Bosnia and Herzegovina, 8 June), with some  
40 participants;
  ‘NPS: methods for analysis of markets and new trends’ 
(Tirana, 13-14 June), with 20 participants.
I Emerging trends and threats 
The detection and monitoring of new trends and threats 
remained one of the key tasks of the agency in 2017.  
The activities in this field reflect an increasing recognition 
of the importance of facilitating the development of early 
responses to potential threats by strengthening the systems 
for identifying and tracking new and emerging trends.
Detecting new trends: the EMCDDA trendspotter 
methodology
A trendspotter study is a rapid information assessment 
that uses multiple social research methods to explore a 
topic of interest or concern. The approach was developed 
and has been used by the EMCDDA since 2011 as a tool to 
complement other routine drug monitoring methodologies.  
It has generally been utilised to explore emerging phenomena 
and new trends that are in their infancy and/or not covered 
by existing data sets. A handbook is being developed by the 
agency (for publication in 2018), to support the use of the 
methodology by EMCDDA staff and partners alike. 
In that regard, the EMCDDA carried out a ‘Trendspotter 
workshop for National Focal Points’ in July 2017, which was 
attended by 18 participants from seven countries, who learned 
how to conduct a trendspotter exercise at national level 
based on the methodology laid down in the draft trendspotter 
handbook. At the end of 2017, the first national trendspotter 
study meeting was held in Copenhagen, following the same 
trendspotter methodology and accompanied by an EMCDDA 
support team.
Furthermore, at the Second COPOLAD II Annual Meeting of 
National Drugs Observatories, which took place in November 
2017 in Lisbon, the EMCDDA delivered a training workshop on 
the trendspotter methodology.
Finally, a trendspotter study carried out in 2016 on ‘High-risk 
drug use and new psychoactive substances’ identified  
15 European countries where there is evidence that NPS 
in prison settings is an issue of concern. The results of the 
study were published in 2017. Based on them, the EMCDDA 
launched a trendspotter study on NPS use in prison in 2017. 
This will result in an in-depth analysis of the topic, providing 
different insights and perspectives. 
New data sources for drug monitoring — European Drug 
Emergencies Network expanded reach in 2017
Supported by the EMCDDA, the European Drug Emergencies 
Network (Euro-DEN Plus) monitors drug-related emergency 
presentations across Europe to provide unique insight into 
acute health harms related to drug use (see Figure 11). 
In the course of 2017, the network expanded its reach by 
collecting data from new hospital ‘sentinel’ centres in eight 
European cities. The eight new centres bring the network to a 
total of 29 sentinel centres in 21 European countries.
In March 2017, the EMCDDA and Euro-DEN Plus held a two-
day network meeting in Tallinn, Estonia, aimed at providing 
an overview of the project and its data collection model, 
specifically for the new centres in Latvia and Lithuania. 
TRENDSPOTTER
STUDIES
Rapidity
focus on speed of 
data collection and 
reporting
Team approach
multiple investigators 
and shared 
responsibilities
Multidisciplinary 
engagement
health and social sciences, 
law  enforcement, forensic 
sciences, drug user 
perspectives
Multi-level 
analysis
local, city, regional, 
national, European level; 
use of mixed methods
Mixed methods
qualitative and 
quantitative 
approaches
Triangulation 
of data
for analysis and for ensuring 
validity of results
FIGURE 10. Characteristics of trendspotter studies
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Testing the waters — Third international conference on 
wastewater analysis in Lisbon
In 2017, the EMCDDA continued its collaboration with the 
SCORE group. This Europe-wide network works to standardise 
the approach to wastewater analysis and coordinate national 
studies by analysing wastewater in over 50 European cities 
and 20 countries in Europe to explore the drug-taking 
behaviours of their inhabitants. 
Leading European and international experts met in Lisbon 
from 26 to 27 October 2017 to review the state of the art of 
the rapidly developing scientific area of wastewater-based 
epidemiology. They gathered at ‘Testing the waters 2017’, 
the Third international conference on wastewater analysis, 
organised by the SCORE group and the EMCDDA. The 
conference took place during Lisbon Addictions 2017. 
One of the main objectives of the conference was to bridge 
the fields of wastewater-based epidemiology and more 
established drug epidemiology. It examined the current 
applications and future prospects for this innovative drug 
monitoring approach. 
I Situation, responses and trend analysis    (Key area 3) 
This area encompasses the core monitoring and analysis 
activities of the EMCDDA, which provide an annual  
state-of-the-art overview of drug demand and supply, together 
with the responses aimed at tackling them and the core trends 
in these domains. These activities are based on established 
tools and processes that are regularly assessed to ensure that 
they are fit for purpose, complemented by the development 
of new ones as necessary. Together, these methodological 
activities ensure the relevance and efficiency of the EMCDDA’s 
core monitoring system. Moreover, it is of utmost importance 
that this system provides valid, reliable and accurate 
information, in order to inform sound decisions for policy  
and practice.
Ongoing monitoring and analytical work was carried out 
throughout the year, and this fed into the key outputs produced 
by the agency. These outputs are mainly presented  
in Key area 1.
I Monitoring drug demand
In terms of monitoring drug demand, the agency relies on its 
well-established key epidemiological indicators (KIs), which 
include the prevalence and pattern of drug use in the general 
population (based on a general population survey (GPS));  
the prevalence and patterns of high-risk drug use (problem 
drug use (PDU) indicator); the number and characteristics of 
drug users contacting drug services, in particular treatment 
services (treatment demand indicator (TDI)); the number of 
drug-induced deaths and mortality among drug users (drug-
related deaths (DRD) indicator); and infectious diseases 
related to drug use (drug-related infectious diseases (DRID) 
indicator).
Although these indicators are now established, further 
methodological improvements are necessary, to ensure 
that they remain fit for purpose. To that end, work continued 
in 2017, and several projects were implemented to further 
develop these KIs. This was supported by the Reitox NFPs and 
other experts in the EMCDDA’s network. The interaction with 
these networks was ongoing, through regular contacts and 
technical support, and culminated in annual expert meetings 
that were organised by the agency at its premises in Lisbon 
(see Table 2).
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FIGURE 11. Location of Euro-DEN Plus centres
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The ‘European Web Survey on Drugs’ project, which started 
with a first wave of six countries in 2016, entered its second 
phase in late 2017 with an additional nine countries running 
the survey. The survey targets people over 18 years of age 
who have used one or more drugs over the last 12 months. 
The promotion of the surveys was carried out at national level 
by each of the focal points involved, with the support of other 
national partners. The EMCDDA released a video in nine 
languages in order to promote the survey around Europe. The 
results of the first two phases will be used to enhance the drug 
market size estimates, to be published in the third EU Drug 
Markets Report in 2019.
Following the publication of the European School Survey 
Project on Alcohol and Other Drugs (ESPAD) study report in 
2016, in 2017 the EMCDDA continued working closely with 
ESPAD principal investigators to exploit the current survey 
results and to coordinate the activities necessary for the next 
round of ESPAD, which is planned for 2019. The EMCDDA 
fulfilled its coordination tasks, which included the hosting of 
two ESPAD Steering Group meetings in January and May 2017 
as well as the organisation of the ESPAD Assembly, which took 
place on 19-21 November in Lisbon. 
I Harm reduction
In 2017, the EMCDDA had the opportunity to join efforts with 
traditional EU and international partners to organise two major 
events for the area: 
  ‘Hepatitis week’ in Lisbon from 12 to 16 June: the week 
kicked off with a two-day meeting of the hepatitis B and C 
network of ECDC followed by the regular annual meeting 
of the EMCDDA DRID network of national experts. The 
event brought together for the first time international 
experts from the EMCDDA DRID expert network and 
the ECDC hepatitis network. This was followed by 
the publication in November of an EMCDDA Rapid 
Communication based on the DRID network meeting. 
  The ‘EMCDDA/WHO Health in Prisons Programme (HIPP)’ 
conference. The conference was held on 11-12 December 
at the EMCDDA and focused on drug addiction. Around 
100 representatives of WHO European countries and 
academics and prison experts, including international 
experts in the field, participated in the conference.
In the prison area, the EMCDDA released a series of new 
resources (see Key area 1): 
  Final version of the questionnaire on drug use among 
prisoners at European level (European Questionnaire on 
Drug Use among Prisoners (EQDP)): The questionnaire 
is the result of several years of work in the field of drugs 
and prison, which has included the agreement of a 
methodological framework or monitoring drug and prison 
in Europe, the analysis of existing questionnaires and 
a discussion among high-level experts from several 
European countries and international organisations.
TAbLE 2. Main network meetings held in Lisbon in 2017
Meeting Dates
Expert meeting on the epidemiological indicator 
patterns and trends in drug use (GPS)
6-7 
June
Expert meeting on the epidemiological indicator PDU
8-9 
June
DRID expert meeting 15-16 June
18th meeting of the Legal Correspondents of the 
European Legal Database on Drugs (ELDD)
13-14 
September
Expert meeting on the epidemiological indicator 
DRD
18-20 
September
EMCDDA TDI/treatment expert meeting
20-21 
September
Fifth annual meeting of the EMCDDA Reference 
Group on Drug Supply Indicators
3-4 
October
17th annual meeting of the Reitox EWS Network
5-6 
December
FIGURE 12. Multilingual videos promoting the European 
Web Survey on Drugs
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  In November, the EMCDDA released a joint systematic 
review with ECDC on whether or not active case finding 
can help reduce communicable diseases in prisons  
(see Key area 1). The findings from this systematic review 
will serve as the evidence base for the development of 
ECDC-EMCDDA public health guidance on active case 
finding for communicable diseases in prison settings to be 
released in 2018.
  A trendspotter study meeting was held in December 2017 
on the topic of ‘NPS in prison’ (see Key area 2).
In the area of DRD, the agency released two reports in 2017:
  EMCDDA assessment of drug-induced death data and 
contextual information in selected countries;
  An overview of the drug-related deaths (DRD) key 
indicator.
Further work on the development of new methodological 
frameworks on the mapping of e-health and m-health (mobile 
health) applications as well as on the rapidly expanding area 
of NPS was also carried out during the year.Further steps 
were also made towards improving our understanding of the 
coverage of treatment services across the EU. 
In March, the EMCDDA published a European Facility Survey 
Questionnaire (EFSQ) package.
The aim of the EFSQ is to collect information from the facilities 
across drug treatment systems on their administrative 
characteristics, client utilisation, staffing and quality 
management, and core interventions, while accounting for 
their diversity.
The EFSQ was developed by the EMCDDA in collaboration with 
the Reitox network of NFPs, WHO and the UNODC.
I Monitoring drug supply 
In 2017 the EMCDDA completed the conceptual framework 
for monitoring drug markets, crime and supply reduction. The 
agency’s current thinking on the conceptual framework for 
monitoring drug markets, crime and supply reduction was 
presented in an EMCDDA Paper launched in December: 
‘Developing drug supply monitoring in Europe: current 
concepts’ (see Key area 1). The paper presents a snapshot 
of the development of the EMCDDA’s conceptual framework 
for supply monitoring (see Figure 14). The topic was also 
presented at the Annual Conference of the International 
Society for the Study of Drug Policy (ISSDP), and as a poster, 
entitled ‘The future of drug supply monitoring in Europe’, 
during Lisbon Addictions 2017. 
A few other resources developed in this area are also 
presented in Key area 1.
FIGURE 13. European Facility Survey Questionnaire — 
resources on the EMCDDA website
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FIGURE 14. Drug supply monitoring system
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Furthermore, incremental progress in implementing the 
reporting instruments on drug supply and supply reduction 
was made through the analysis of data availability on drug 
seizures and drug law offences, as well as on drug purity and 
drug prices. Data collections on drug production (synthetic 
drugs, cocaine secondary extraction and cannabis) were 
strengthened in close cooperation with Europol.
The work of the EMCDDA Reference Group on drug supply 
indicators, including representatives from each Member State, 
the EC (DG Migration and Home Affairs, and Eurostat), Europol 
and Eurojust, was essential for reaching the objectives in this 
area. During 2017, the recommendations arising from the 
review of the Reference Group were implemented, and the 
annual meeting of the group convened on 3-4 October.
I Monitoring drug policies and laws
Monitoring of drug laws and policies continued in 2017 with 
a focus on emerging issues, such as cannabis policy and 
legislation. A large number of resources on this topic were 
released (see Key area 1). 
The annual meeting of the legal correspondents of the 
European Legal Database on Drugs (ELDD) was organised on 
13 to 14 September in Lisbon, as a means to further improve 
the sharing of knowledge and expertise among Member States.
I Information collection and management    (Cross-cutting area A) 
I The annual information collection exercise
A main component of the EMCDDA’s reporting system is the 
national reporting package, which is implemented every year 
in close collaboration with the NFPs. This reporting package 
provides data delivered through a set of standard instruments 
via Fonte (the agency’s online data collection system) and a 
structured commentary on the drug situation (the Workbooks), 
reported via the Reitox Extranet.
In addition to maintaining the data collection system, the 
work in 2017 was focused on developing a new product in 
cooperation with the Reitox NFPs: the web-based CDRs, 
derived from the information provided by the Workbooks.  
As a result, 30 CDRs were published for the first time in June 
(see also Key area 1).
Another key task in this area was to further develop and 
maintain a fully operational EDND, which is the main working 
tool of the EU EWS (see Key area 2). The EDND stores the 
information related to all the NPS monitored to date (more 
than 670). This information is updated on a daily basis. A total 
of 312 substance profiles were updated in the EDND in 2017, 
which gives an indication of the considerable effort required to 
maintain this database.
In parallel, the project to align the EDND to the growing 
demands of the EWS continued in 2017. This technological 
redevelopment of the EDND is a major line of work for the 
agency, and it is being undertaken in different phases in order 
to ensure the inclusion of advanced technical functionalities.
I Management of the Reitox national focal points
In fulfilling its tasks, the EMCDDA relies on the European 
Information Network on Drugs and Drug Addiction — the 
Reitox NFPs. The NFPs exercise the critical role of providing 
national data from the 30 countries that report to the EMCDDA, 
namely the 28 EU Member States, Norway and Turkey  
(see Figure 15).
Therefore, the network will play a key role in the successful 
implementation of the EMCDDA Strategy 2025 and the 
achievement of its strategic goals. 
In that regard, a key development in 2017 was the adoption 
of the new Reitox Development Framework by the Heads 
of the NFPs (HFPs) at their meeting in November. The 
document was prepared by a joint working group composed 
of representatives of the EMCDDA and of the NFPs. It defines 
the main priorities for the network, in line with the EMCDDA 
Strategy 2025. To that end, four strategic objectives, and their 
accompanying specific objectives, will guide the future work of 
the network (see Figure 16).
Source: Reitox development framework: new perspectives for the network 
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FIGURE 15. National focal points: heart of network
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Strengthening the organisational capacity of the NFPs is 
also vital for ensuring their sustainability. To that end, the 
accreditation project developed in the previous years was 
piloted in 2017 in six countries. The experienced gained was 
used for improving the first developed tool (a self-assessment 
questionnaire), which was approved at the HFP meeting in 
November, for further implementation by the network.
Regular communication was also ensured between the 
EMCDDA and the NFPs throughout the year. Key issues were 
discussed more extensively at the biannual meetings of the 
HFPs and at the two technical meetings organised during the 
year.
Furthermore, four Reitox Academies were organised with 
Reitox NFPs, on the following topics:
  ‘New threats and challenges in drug monitoring and 
responses’, Tallinn, 26-28 September (22 participants);
  ‘Reporting on drug-related public expenditure’, Lisbon,  
27 October (15 participants);
  ‘Implementation of the Problem Drug Use indicator’, 
Lisbon, 5-7 December (13 participants);
  ‘Experiences of violence among clients of drug help 
services’, Vienna, 11 December (37 participants).
Throughout the year, the EMCDDA continued to support 
the work of the NFP towards the implementation of the 
EMCDDA work programme. In the case of the NFPs from the 
28 EU Member States, a key feature of this support is the 
co-financing of their activities, covered by a grant agreement 
without which the network could not accomplish their tasks. 
The management of these grant agreements is also part of 
the overall organisational capacity of the NFPs. In the context 
of these grant management activities, the EMCDDA carried 
regular on-site audit missions: the countries randomly covered 
in 2017 were Latvia, Poland and Romania.
I Quality assurance   (Cross-cutting area B)
In 2017, the EMCDDA continued to improve the quality of its 
analysis and outputs. Quality assurance of the scientific work 
is a prerequisite for the recognition of the EMCDDA as the 
reference point on drugs in Europe, so it is an area of critical 
importance for the agency. 
To that end, further progress was achieved in the definition 
and implementation of the data quality framework, of the 
indicators for the Internal statistics code of practice and 
of the documentation around data/information flows and 
processes. Work in this area was supported by the audit on 
the ‘Management of Data Collection, Validation and Quality 
Assurance in the EMCDDA’, which was performed by the 
Internal Audit Service of the EC in June. Based on the final 
report of the audit, the EMCDDA drafted a follow-up action 
plan, which was endorsed by the Management Board in 
December.
Maintain the Reitox monitoring system t for purpose
Strengthen the role of the NFPs 
in supporting decision-making and action at national level
Improve the overall quality of the processes 
and deliverables of the NFPs
Improve the coordination of, and cooperation within, 
the Reitox network
FIGURE 16. Reitox Development Framework
TAbLE 3. Reitox meetings in 2017
Meeting Dates
56th Reitox HFP meeting
30 May 
to 1 June 
57th Reitox HFP meeting
28 November 
to 1 December
Technical meeting ‘Revision of national reporting: 
Structured Questionnaires (SQ's) and workbooks’
26 April
Technical meeting ‘Revision of national reporting 
guidelines; Reitox Development Framework; 
Accreditation’
12 October
  Improve the completeness and quality of routine data 
collected through the Reitox network
  Increase the capacity of the NFPs to track and report on new 
developments, emerging trends and real-time data
  Increase the capacity of the NFPs to collect and analyse data 
on public safety and security
  Strengthen the capacity of the NFPs to promote and support 
evidence-based decisions
  Reinforce the partnership between the Centre and NFPs to 
improve the information service to national decision-makers 
and practitioners
  Assuring minimum quality standards for the NFPs
  Increase horizontal cooperation between the NFPs
  Increase the external visibility of the Reitox network as a whole
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I New mandate of EMCDDA Scientific Committee
The EMCDDA Scientific Committee embarked on a new 
three-year mandate on 1 January 2017. As decided by the 
Management Board, the current members — 15 top-level 
scientists selected in 2013 following the publication of a 
call for expressions of interest in the Official Journal of the 
European Union — will continue to serve as guardians of and 
advocates for the scientific integrity of the agency until the end 
of 2019. 
At its meeting held in May, the Scientific Committee elected 
Anne Line Bretteville-Jensen and Catherine Comiskey as new 
Chair and Vice-Chair respectively, for the 2017-19 mandate.
During the year, the members of the Scientific Committee 
adopted a formal opinion on the PD 2018-20 and provided 
input on the agency’s main projects and scientific publications, 
in line with the guiding principles for the review of selected 
publications. Members of the Scientific Committee were also 
actively involved in the EMCDDA Scientific Award process, as 
reviewers, nominators of articles and members of the jury.
I Cooperation with partners   (Cross-cutting area C)
In line with its strategic priorities, in 2017 the EMCDDA 
continued to enhance the exchange of information and 
knowledge with its European and global partners. Priority was 
given to the activities concerning the provision of technical 
support to EU institutions and the EU Member States  
(for details, see Key area 1). 
Other EU agencies, in particular the ones from the JHA cluster, 
as well as ECDC and the EMA, were also key partners  
(see Key areas 1, 2 and 3). 
Regarding our global partners, cooperation was strengthened 
with international organisations, in particular with the UN 
family (UNODC and WHO) (see Key areas 1, 2 and 3). 
In terms of cooperation with third countries, the priorities were 
the successful completion of the IPA 5 technical assistance 
project, which started in 2015, and the successful kick-off of 
the IPA 6 programme, which covers the period July 2017 to 
June 2019. 
I Cooperation with other EU bodies 
EMCDDA chaired JHA agencies network 
In 2017 the EMCDDA chaired the JHA agencies 
network (4). The agencies work together on a wide range of 
issues, including human trafficking, migration and border 
management, drug trafficking and combatting organised crime. 
Chairing the network involved, among other tasks, organising 
the JHA agencies’ directors’ meeting, routine network 
meetings and other sub-meetings and seminars in accordance 
with the plans and priorities established by the network; 
preparing joint statements or common papers, when 
necessary; and presenting the work of the network to COSI 
and LIBE Committee. 
The theme chosen for the 2017 mandate was the internet. 
A conference was organised in April on ‘The internet for 
criminal purposes — challenges and opportunities for the 
work of the JHA agencies’. It looked at how cyberspace has 
influenced criminal activities and explored future issues such 
as monitoring drug supply on darknet markets.
(4) The JHA agencies’ network was established in 2006 to boost cooperation in the 
migration and security fields. The nine agencies play key advisory, operational and 
coordination roles in implementing EU priorities in the areas of freedom, security 
and justice. 
The four winners of the 2017 EMCDDA scientific award 
were honoured in Lisbon on 25 October at the seventh 
annual award ceremony hosted by the EMCDDA. The 
acclaimed writers received a non-monetary prize and 
presented their articles during Lisbon Addictions 2017. 
The prize, inaugurated in 2011 by the EMCDDA and its 
Scientific Committee, celebrates scientific writing and 
distinguishes high-quality research in the field of illicit 
drugs. 
The four winners (primary authors) were Annelies 
Cannaert, PharmD (Belgium), Professor Frederik 
L. Altice, MD (United States), Melvin Soudijn, PhD 
(Netherlands) and Mascha Nuijten, PhD (Netherlands).
EMCDDA scientific award 
Alexis Goosdeel, EMCDDA Director, Catherine Comiskey, Vice-Chair, and 
Anne Line Bretteville-Jensen, Chair of the Scientific Committee  
© EMCDDA, Paulo Silva
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On 28 November, the EMCDDA hosted the meeting of the 
network’s directors to take stock of what the JHA work 
programme had achieved in 2017 and the way forward 
in 2018. The high-level event brought together Dimitris 
Avramopoulos, European Commissioner for Migration, Home 
Affairs and Citizenship; the Director-General of DG HOME and 
Director-General of DG JUST; the JHA agency directors; and 
key stakeholders in the network.
At the end of its successful year as chair, the EMCDDA handed 
over the task to the European Institute for Gender Equality 
(EIGE), the agency which will fulfil this role in 2018. 
During the year, the successful collaboration developed in 
previous years with other EU agencies continued. It resulted in 
joint outputs, knowledge exchange through technical meetings 
and training initiatives, and input to other joint activities 
(presented in Key areas 1, 2 and 3). 
The EMCDDA also contributed actively to the discussion 
on issues of common interest to the agencies, as part of 
the network. The agency was an active contributor to the 
Performance Development Network, where it chaired the 
working group in charge of developing and submitting to 
the EC a proposal to review the current Guidelines for the 
Programming Document for all the EU decentralised agencies. 
The EMCDDA also contributed to the Heads of Communication 
and Information Network, and to other specialised sub-
networks. Furthermore, in 2017 it was decided that the 
EMCDDA will chair the EU Agencies’ Network on Scientific 
Advice (EU-ANSA) in 2018.
8.5% of all
analytical products
Justice and Home Affairs agencies network
Inter-agency activities in 2017
25% of all
training activities
≈60
Inter-agency activities
125
Inter-agency
training activities
23
in force
5 signed in 2017
≈50
Inter-agency activities
2
events
100 participants
188
Products
16 joint outputs
Migration, asylum and 
border management
Security and serious 
organised crime
2017 theme
Internet/cyberspace
JHA training 
activities
Analytical 
products
Formalised
working arrangements
 
Increase on 2016
 
Increase on 2016
6 Keynote speakers9 JHA agencies
and 6 other partners
Source: EU Justice and Home Affairs agencies’ cooperation in 2017  
(final report)
FIGURE 17. Justice and Home Affairs agencies network — 
Inter-agency activities in 2017
From left to right: Georgi Arabadzhiev, COSI Chair/Bulgaria – Deputy Secretary General, Ministry of Interior; Erkki Koort, COSI Chair/Estonia – Deputy Secretary General 
for Internal Security Policy, Ministry of Interior; Matthias Ruete, DG HOME; Ladislav Hamran, President of Eurojust; Nathalie Pensaert, Council Secretariat DG D for 
Justice and Home Affairs, Director Directorate 2 – Justice; Michael O’Flaherty, FRA Director; Alexis Goosdeel, EMCDDA Director; Dimitris Avramopoulos, European 
commissioner for migration and home affairs; Rob Wainwright, Europol Director; Virginija Langbakk, EIGE Director; Berndt Körner, Deputy Executive Director, Frontex; 
Krum Garkov, Executive Director of EU-LISA; Detlef Schröder, CEPOL Executive Director; Tiina Astola, Director-General DG JUST; Polydoros Frantzeskakis, Head of 
Department of Administration, EASO.
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I Cooperation with international organisations
Cooperation was strengthened with international organisations, 
in particular with the UN family (UNODC and WHO), with a 
view to maximising synergies and avoiding duplication of effort 
(for details, see Key areas 1, 2 and 3).  
This concerned particularly the NPS area (see Key area 2). 
Among other tasks, the two organisations co-organised the 
Fifth international conference on NPS, which took place in 
Vienna in October. In addition, the EMCDDA has undertaken 
technical discussions with the UNODC on how to improve data 
collection and how to facilitate inter-agency collaboration.
The EMCDDA continued to cooperate with both the WHO 
headquarters in Geneva and the WHO Regional Office for 
Europe. Cooperation with WHO Europe in recent years has 
covered prison and infectious diseases, whereas cooperation 
with WHO headquarters has focused on quality standards of 
interventions and the monitoring of treatment systems. 
Reflecting the EMCDDA’s world-leading expertise in NPS and 
the role it plays, particularly with respect to early warning, 2017 
saw the EMCDDA and WHO headquarters strengthen their 
growing cooperation in this area too (see Key area 2 for details). 
I Cooperation with third countries 
In December 2017, the EMCDDA Management Board adopted 
the ‘EMCDDA International Cooperation framework 2018-25: 
maximising value from cooperation with third countries and 
international organisations towards a healthier and a more 
secure Europe’. The document updates the EMCDDA Strategy 
on International Cooperation adopted in 2007 and aims to fully 
align the activities of the agency in this area with the EMCDDA 
Strategy 2025. To that end, the work of the agency will be 
articulated around the following three strategic objectives: 
1. Better understand the global drug situation including the 
key drug policy developments occurring internationally.
2. Improve the EMCDDA stakeholders’ knowledge of the 
drug situation in third countries, in particular those 
bordering the EU, in order to understand its implications 
for public health in the EU and its impact on the European 
drug market.
3. Support EU policies and initiatives in the drugs field.
I Candidate and potential candidate countries
In 2017 the EMCDDA completed the implementation of the 
IPA 5 technical assistance project for IPA beneficiaries and 
initiated IPA 6, a two-year cooperation project which will run 
until 30 June 2019. 
Project objectives and key achievements:
Objective 1:  consolidate cooperation with each IPA 
beneficiary at institutional level
  The EMCDDA organised national stakeholder meetings 
in each of the six beneficiaries’ capital cities to ensure 
national adherence to the project goals and expected 
outcomes.
Objective 2: foster scientific cooperation in data collection, 
analysis and interpretation
  Activities included a data collection exercise on assessing 
drug seizure data in the region, which included training 
sessions and analysis of national data. 
  In cooperation with the UNODC, the EMCDDA supported 
the assessment of drug treatment availability and service 
needs at national level by helping interested countries 
carry out drug treatment facility surveys. 
Overall objective: 
countries for their participation in EMCDDA activities and the 
Reitox NFPs
24 months (July 2015-June 2017)
Budget: EUR 600 000
six candidate and potential candidate countries: 
Albania, Bosnia and Herzegovina, the former Yugoslav Republic 
of Macedonia, Kosovo, Montenegro and Serbia 
FIGURE 18. Implementation of the IPA 5 project in 2017
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  Also financed under the project was the implementation of 
the first national general population surveys in the former 
Yugoslav Republic of Macedonia and in Montenegro.
  The EMCDDA supported countries in developing national 
EWSs on NPS under this objective. 
Objective 3: develop, increase and promote the added value of 
the cooperation
  National drug reports for several beneficiaries were 
prepared in close cooperation with the national experts.
  Inputs were provided to support activities aimed 
at supporting the overall enlargement process and 
development of national legislation in the area of drugs.
  Visibility was increased through communication of project 
activities via the EMCDDA digital channels and making 
some EMCDDA flagship products more accessible to the 
national audiences in the beneficiaries.
To mark the end of the EC-funded EMCDDA-IPA 5 project 
in June 2017, the EMCDDA organised a final conference in 
Sarajevo, with the support of the Ministry of Security of Bosnia 
and Herzegovina. It brought together the EMCDDA, national 
correspondents of the project beneficiaries, the national 
experts who contributed to the projects, EU delegations and 
international organisations, in order to review the results of the 
IPA 5 project.
On 1 July, the EMCDDA embarked on IPA 6, a two-year 
cooperation project that will run until 30 June 2019. The 
project has a budget of EUR 340 000 and will strengthen 
cooperation with the six IPA beneficiaries in the Western 
Balkans, preparing them for participation in the work of the 
agency and the Reitox network.
I Other third countries
The EMCDDA and the Federal Office for Public Health of 
Switzerland (FOPH) signed a Working Arrangement on 
12 September 2017. The signatories were Alexis Goosdeel, 
EMCDDA Director, and Pascal Strupler, Director of the FOPH.
The agreement includes steps to enhance the knowledge base 
on the drug situation and responses to it, through cooperation 
in the area of data collection methodology and through data 
sharing in key areas. It also allows the two bodies to exchange 
experience on health and social responses to drug problems 
and pays special attention to the exchange of expertise and 
data in the area of NPS. 
Finally, the EMCDDA continued to contribute its know-how 
to EU drug-related regional programmes, as requested by 
the EC. This included support to the implementation of the 
new COPOLAD II project and to the CADAP 6 project, which 
are funded by the EC in Latin America and Central Asia 
respectively.
Signature of Working Arrangement with Switzerland: Pascal Strupler, 
Director of FOPH and Alexis Goosdeel, EMCDDA Director
© EMCDDA, Nuno Saraiva
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 CHAPTER 3
  Management and leadership
I  Corporate area Governance
2017 was the first year under the EMCDDA Strategy 2025, 
adopted by the Management Board in December 2016. 
In this context, the focus for the Corporate area Governance 
was to set the necessary guidance and direction for the 
successful transition of the agency towards the new long-term 
strategic framework while continuing to perform the tasks 
set out in its Founding Regulation (recast) and achieve its 
objectives in an efficient way.
I EMCDDA Director — main activities 
The Director, through his external activities, contributed to 
increasing the visibility of the EMCDDA and consolidating the 
credibility of its work by building and improving partnerships 
(for further details, see also Key area 1). 
For instance, Mr Goosdeel strengthened relationships with the 
EP. The Director gave presentations at three meetings of the 
LIBE Committee. He had meetings with several MEPs, who 
were members of the LIBE and ENVI Committees, throughout 
the year on issues concerning the work of the agency. 
On 10 February, Mr Goosdeel met with Mr Andrea Raimondi, 
Assistant of MEP Monica Macovei (Romania, member of the 
Committee on Budgetary Control (CONT) and of the LIBE 
Committee). During the week of 9-13 October, Mr Goosdeel 
met with the MEPs Adina-Ioana Vălean (Romania, Chair of the 
ENVI Committee), Bart Staes (Belgium, substitute member of 
the ENVI Committee) and Tomáš Zdechovský (Czech Republic, 
member of the LIBE Committee). On 23 November, the 
Director had meetings with MEPs Monica Macovei (Romania) 
and the assistant of MEP Miriam Dalli (Malta, member of 
the ENVI Committee and substitute member of the LIBE 
Committee).
On 10 October, the Director met with Ms Nathalie Pensaert, 
Director for Justice within the Directorate-General D — Justice 
and Home Affairs at the Council of the European Union. 
He also participated, together with Ms Pensaert and other 
representatives of the Council, in a coordination meeting 
between the EMCDDA and the Council on 22 November in 
Brussels.
Throughout the year, the Director had regular meetings with 
the European Commission’s services, including meetings with 
the Cabinet of Commissioner Avramopoulos and the Director-
General of Migration and Home Affairs, Matthias Ruete, and 
with the Cabinet of Vytenis Andriukaitis, Commissioner for 
Health and Food Safety. Several meetings were held with Ms 
Floriana Sipala, Head of the Organised Crime and Drugs Policy 
Unit at DG Migration and Home Affairs.
The 2017 EDR was launched to the international press 
at a press conference in Brussels on 6 June by Dimitris 
Avramopoulos, European Commissioner for Migration, Home 
Affairs and Citizenship. The Commissioner was joined by the 
Chair of the EMCDDA Management Board, Laura d’Arrigo, and 
the EMCDDA Director, Alexis Goosdeel.
The Director welcomed the European Commissioner for 
Research, Science and Innovation, Carlos Moedas, who paid 
an informal visit to the EMCDDA on 8 May 2017. The European 
Commissioner in charge of Security Union, Mr Julian King, 
visited the EMCDDA on 6 November 2017 for an update 
on the agency’s work in the area of security. Commissioner 
Dimitris Avramopoulos, in charge of Migration, Home Affairs 
and Citizenship, participated in the meeting of Directors of JHA 
agencies, which took place on 28 November at the EMCDDA in 
Lisbon and was chaired by the EMCDDA Director.
The Director met Ms Myria Vassiliadou, EU Anti-Trafficking 
Coordinator at DG Migration and Home Affairs, on 12 October. 
Meetings with Mr John Ryan, Director at DG Health and Food 
Safety (DG SANTE), and several Heads of unit, were scheduled 
during a visit on 5 to 6 December to Luxembourg to discuss 
the EMCDDA’s cooperation with this Directorate-General of 
the EC. 
With regard to building relationships with the other EU 
agencies, the Director participated in the ‘informal strategy 
meeting’ of Directors of JHA agencies on 29 and 30 May in 
Malta. The Director participated in the meeting of Heads of EU 
General Report of Activities 2017 Chapter 3 I Management and leadership
39 / 81
agencies on 6 to 7 July at the European Food Safety Agency 
(EFSA) in Parma. Mr Goosdeel attended a conference on drug 
policy on 27 and 28 June in Warsaw and took this opportunity 
to visit the headquarters of the European Border and Coast 
Guard Agency (Frontex). On 22 November, the Director opened 
a meeting of EU-ANSA, which was hosted and co-chaired 
by the EMCDDA. He chaired the meeting of Heads of JHA 
agencies, which took place on 28 November at the EMCDDA in 
Lisbon in the presence of Commissioner Avramopoulos. 
In March 2017, the Director participated in the Special 
Segment of the 60th session of the Commission on Narcotic 
Drugs organised by the UNODC and held in Vienna, as well as 
in the bilateral EU-US meeting and in the side event on ‘New 
perspectives on information communication’. 
Mr Goosdeel participated in the HIV conference entitled 
‘Fast-track the end of AIDS in the EU — practical evidence-
based interventions’, which was organised under the Maltese 
Presidency, in collaboration with ECDC, on 30-31 January in 
St Julians. The Director had meetings on 7 February in Paris 
with the Chair of the Management Board and the President 
of MILDECA (Mission interministérielle de lutte contre les 
drogues et les conduites addictives), Ms Danièle Jourdain-
Menninger, and on the same day with the Head of the French 
NFP, Mr François Beck, followed by a meeting with Prof. Dr 
Henri Bergeron, member of the EMCDDA Scientific Committee. 
The Director paid visits to Bulgaria, the Czech Republic, Greece 
and Luxembourg.
Mr Goosdeel participated in several events organised by 
the Portuguese authorities, had bilateral meetings with EU 
Member State ambassadors and attended a number of 
receptions held to mark national days at the embassies of 
various EU and non-EU countries. The Director also gave a 
presentation at the 'XIV International Security Conference' on 
28-29 September in Rio de Janeiro, Brazil.
I First year of implementation of the Strategy 2025
The first year under the new EMCDDA Strategy 2025 was 
2017. The focus was therefore placed on designing and 
implementing a corporate change management programme 
encompassing the measures necessary for a smooth and 
coherent transition towards the new long-term strategic 
framework of the agency. 
The following elements are part of this complex change 
management exercise (see Figure 19): 
  the refinement and implementation of the new 
organisational structure adopted by the Management 
Board in December 2016 as part of the package proposed 
by the Director to support the Strategy 2025; 
  the alignment of the EMCDDA Programming Document 
(PD) with the Strategy, which provided the framework for 
defining the agency’s priorities and allocating resources 
within the two pillars (Health and Security);
  the development of the Project Management Programme, 
a new corporate initiative which aims to set up a project 
management culture at the EMCDDA and achieve one of 
the key milestones defined in the Roadmap 2020.
These main elements were complemented throughout the 
year by a sustained internal communication effort. Among 
other undertakings, this included the organisation of three 
general staff assemblies (in February, June and September 
respectively) during which the Director updated the staff on 
the state of play in the implementation of the Strategy 2025, 
particularly as far as the internal reorganisation measures were 
concerned. In addition, regular meetings between the Director 
and the Staff Committee of the agency were organised, as well 
as unit meetings or bilateral meetings with the staff concerned 
in the various aspects of the ongoing change management 
programme.
Internal
reorganisation
New organisational structure 
Organisational design project: 
redenition of missions and 
key functions for the units
Recruitment management 
positions
Integrated strategic and 
operational framework
Alignment of the 
Programming Document 
(PD): long-term strategic 
objectives translated into 
short-term operational 
priorities, outputs and results
Project Management
Programme
Adoption and implementation 
Project Management Squared 
(PM2) methodology
Development and 
implementation Management 
Information System (MIS)
Change management programme 
PD
Strategy 2025
Roadmap 2020
Management training  
Ongoing internal 
communication  
STRUCTURE IN PLACE CORPORATE TOOLS AND PROCESSES IN PLACE
FIGURE 19. Change management framework
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New organisational structure
On 1 January 2017, the new organisational structure entered 
into force. It aims to support the implementation of the 
Strategy 2025 and ensure delivery of the expected results. 
The main change was the creation of a new unit, the Public 
health unit (HEA), which will be in charge of implementing 
the priorities defined under the Health pillar of the Strategy 
(except for the activities related to the implementation of the 
EWS). The other scientific unit — the former Supply reduction 
and new drugs unit, now named Risks to public safety and 
security (SAS) — will maintain its role and be in charge of 
implementing the priorities defined under the Security pillar of 
the Strategy and the EWS.
As a follow-up to this decision, the selection procedure for 
the recruitment of the Head of the new Public health unit 
was finalised on 21 July and the successful candidate was 
appointed with effect from 1 October 2017. 
Furthermore, the work of the HEA unit is organised within 
three sectors, namely Support to policy (POS), Support to 
practice (PRS) and Trends and analysis (TAS). These are led by 
Heads of sectors, who were selected by means of an internal 
recruitment procedure in the second half of 2017. 
These changes were informed by the results of an 
organisational design project which started in March 2017. 
The project was carried out by the Heads of unit, under 
the supervision of the Director and with support from an 
external consultant. As part of the project, a review of the 
mission statements of all units took place, along with a clear 
definition of the core functions to be fulfilled by each unit in 
order to ensure that they successfully deliver their expected 
contribution to the Strategy.
Alignment of the strategic planning instruments
As part of its new integrated strategic and operational 
framework (see Figure 20), in 2017 the agency prepared 
and submitted to the Management Board for adoption the 
preliminary draft of the first PD which was fully aligned with 
the Strategy 2025. 
The document, which covers the period 2019-21, was built 
around the three new strategic areas: Health, Security and 
Business drivers. Within these areas, expected results were 
defined in line with the key milestones set up in the  
Roadmap 2020.
The outcome of the exercise was therefore the effective 
translation of the EMCDDA’s long-term strategic priorities 
into concrete, more operational activities that the agency will 
implement during the next three-year programming period. 
Towards a corporate project management approach 
The successful implementation of the Strategy 2025 also 
depends on the optimal performance of the agency, both 
substantive (effectiveness) and operational (efficiency). 
In order to increase efficiency, the agency will pursue the 
development and adoption of a unified corporate project 
management methodology for its applicable activities. To that 
end, the methodology chosen was PM2 (Project Management 
Squared), which is widely used by the EC and increasingly 
used by agencies; therefore, it ensures that the EMCDDA’s 
work practices are aligned with those of other EU bodies. The 
new PM2 project was approved in October 2017,  
for implementation starting from 2018, with support from an 
external consultant (DG Informatics). This will be integrated 
with the other related project, the Management Information 
System (MIS), which started in previous years (see Chapter 4, 
section on Information and communication technology), under 
the umbrella of the broader EMCDDA Project Management 
Programme initiative.
Founding regulation (recast)
Strategy 2025
Roadmap 2020 Roadmap 2025
Mission
Role and mandate of the EMCDDA
Vision, values, goals and strategic objectives
Top-level
milestones
Detailed planning instrument
Programming Documents
2018 2019  2020
2019 2020  2021
2021 2022  2023
2022 2023  2024
2024 2025 2026
2025 2026  2027
2017 2018  2019 2020 2021  2022 2023 2024  2025
FIGURE 20. The EMCDDA’s integrated strategic and 
operational framework 
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I Strategic planning, performance monitoring and    reporting
As mentioned under the previous sub-heading, work in 
2017 focused on the preparation of the new PD 2019-21. 
The preliminary draft of this document was adopted by the 
Management Board on 14 December 2017. On the same day, 
the Management Board also adopted the PD 2018-20. 
In 2017 the agency pursued the further development of its 
performance management system. In order to achieve this, a 
detailed internal management plan was put in place to support 
the planning of activities and the necessary resources to 
implement them and achieve the results defined in the 2017 
work programme. This internal management plan served as 
the basis for the two corporate monitoring exercises that were 
carried out during the year, namely the mid-year monitoring 
and the end-year monitoring, which helped prepare this 2017 
General Report of Activities.
Another key document produced during the year in this 
area was the end-term assessment report of the 2013-15 
Strategy and work programme, which was presented to 
the Management Board on 15 December 2017. The report 
assessed to what extent the specific objectives established 
in the 2013-15 strategy and work programme were attained 
(fully, partly or not at all), based on the level of achievement of 
the key expected results which contributed to each specific 
objective. The exercise will be useful for the preparation of the 
EMCDDA’s next external evaluation, to be conducted in 2018. 
In terms of corporate reporting, the main output was the 
General Report of Activities for 2016, adopted by the 
Management Board through written procedure and published 
on 15 June 2017. This comprehensive report was forwarded to 
the EP, the Council of the EU, the European Court of Auditors 
(ECA) and the Internal Audit Service of the EC, in line with the 
provisions of the EMCDDA Founding Regulation.
I Internal control standards
Pursuant to Article 44.2 of the Financial Regulation applicable 
to the EMCDDA, the EMCDDA Director, in his capacity as 
EMCDDA Authorising Officer, shall put in place the structure 
and internal control systems suited to the performance of his 
duties, in accordance with the minimum standards adopted by 
the Management Board, on the basis of equivalent standards 
laid down by the Commission and having due regard for the 
risks associated with the management environment. 
The Management Board’s Decision DEC/MB/10/06 of 1 July 
2010 adopted the 16 Internal Control Standards for effective 
management and control at the EMCDDA. The implementation 
of this decision has been sought and monitored in a 
systematic manner since then. 
The Communication to the European Commission from 
Commissioner Oettinger (C(2017) 2373 of 19.04.2017) 
sets up a new internal control framework consisting of five 
internal control components and 17 principles, based on the 
Committee of Sponsoring Organizations of the Treadway 
Commission (COSO) 2013 Internal Control Integrated 
Framework. Considering these developments, a revised 
internal control framework was developed by the EMCDDA on 
the basis of the new internal control framework adopted by the 
EC. The document was adopted by the Management Board in 
December 2017.
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 CHAPTER 4
  Supporting the achievement of results
The overall objective for this area in 2017 was to ensure 
that the implementation of the activities planned across the 
different areas of the annual work programme are supported 
by effective management of the available resources and by 
efficient information and communications technology (ICT) 
services.
I  Financial and budget management,  and accounting
The priorities in the financial resources management area are 
effective and timely planning, monitoring and execution of the 
EMCDDA budget, and optimising all the related processes. 
These are complemented by the efficient use of material 
resources.
In this context, the EMCDDA achieved once again an 
outstanding performance in terms of budget execution, with its 
highest ever commitment rate (100 %).
In terms of the procurement execution, the procurement 
plan was put in place and successfully executed in close 
collaboration with all units.
The EMCDDA also participated, as an active member, in the 
annual meeting of the Network of Agencies Procurement 
Officers (NAPO).
I  Human resources
The sound management of existing processes, as required by 
the applicable staff regulations and their implementing rules, 
remained key in 2017.
Another priority was the organisation of appropriate training 
for the agency’s staff, to support the effective implementation 
of the EMCDDA’s new long-term strategy and subsequent 
internal reorganisation (see Corporate area Governance). The 
target of providing an average of three training days per staff 
member (KPI ADM.1.3 — see Annex 4) was overachieved.
As in previous years, the EMCDDA played an active role in 
discussions held by several inter-agency working groups  
in this area.
I  Infrastructure and logistics
In the area of logistics and infrastructure management, 
ensuring a healthy and safe working environment remained 
the key priority in 2017. Further measures to rationalise the 
costs of utilities were implemented during the year, which led 
to achieving an overall reduction of 2.6 % in utility costs.
The identification of health and safety risks for staff remained 
one of the main priorities of the agency. So did increasing 
effectiveness, efficiency gains and cost savings, including 
through further synergies with the European Maritime Safety 
Agency (EMSA).
TAbLE 4. Budget execution
Commitment appropriations 100.0 %
Payment appropriations 94.7 %
Consumption of 2016 (C8) credits 95.0 %
TAbLE 5. Training provided
Total number of training days 373
Training days per staff member (average) 3.6
Budget spent on training (EUR) 89 243
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The information included in the risk registry was adapted 
following the annual risk assessment exercise that was 
delivered in 2017.
The internal EMCDDA Environmental Policy was further 
implemented and an environmental report was delivered in 
2017. The agency continued to contribute to the Inter-agency 
Greening Network.
I  Information and communication technology
The ICT programmes and services are developed and delivered 
in line with the triennial objectives, which are to implement and 
support core business and corporate projects and processes 
and to provide a continuously stable environment which 
supports existing basic and advanced services. 
Concerning the support to core business areas, the following 
activities were given priority in 2017: 
  the maintenance and development of the EMCDDA’s 
established online data collection platforms, namely Fonte 
and the EDND (see also Cross-cutting Area A), and the 
drugs data warehouse;
  keeping the web system functional and further developing 
it: in particular, during the year significant effort was 
invested in migrating large areas of content from the 
internal content management area to the EMCDDA public 
website.
Support was also provided to the corporate areas, particularly 
to the planning and performance monitoring activities, namely 
for the development of the corporate management information 
system (MIS), which is now part of the EMCDDA’s new Project 
Management Programme initiative (see Chapter 3, Corporate 
area Governance), as well as to the human resources and 
financial management processes. 
The optimal allocation and prioritisation of the ICT resources 
was supported by the internal ICT Steering Committee, by 
refining priorities and deciding on the intensity of work to 
be devoted to each activity, depending on the most critical 
organisational needs.
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 CHAPTER 1
 Management Board’s analysis  
  and assessment
The Management Board has analysed and assessed the 
Authorising Officer’s (Director’s) General Report of Activities 
for the financial year 2017.
The Management Board appreciates the performance of the 
Centre in implementing its work programme and welcomes 
in particular the emphasis put by the EMCDDA in 2017 on 
increasing its services to support policy at EU, national and 
international levels.
In assessing the report, the Management Board wished to 
highlight the following achievements:
  The EMCDDA presented its annual overview of the 
European drug situation — the European Drug Report 
(EDR), together with a multimedia EDR package and for 
the first time with 30 Country Drug Reports. The agency 
also published the first edition of Health and social 
responses to drug problems — a European Guide. 
  In terms of support to policy, the EMCDDA continued to 
support drug policy dialogue at EU and national levels, 
and was very active in providing support to the European 
Commission and the External Action Service on activities 
with third countries. The agency attended some 53 key EU 
and international drug policy meetings. Three European 
Commissioners (Dimitris Avramopoulos, in charge of 
Migration, Home Affairs and Citizenship, Carlos Moedas, 
in charge of Research, Science and Innovation, and Julian 
King, in charge of Security Union) visited the EMCDDA. 
The EMCDDA successfully chaired the network of Justice 
and Home Affairs Agencies in 2017. 
  The EMCDDA maintained close communication with the 
EU Member States, in particular with the Reitox network 
of NFPs, and undertook various technical or institutional 
missions in Member States.
  The EMCDDA carried on ensuring continuous and robust 
implementation of the EU EWS on NPS together with its 
partners in the Member States, with Europol and with the 
EMA, reaching the highest number of outputs since the 
entering into force of the Council Decision in 2005. In the 
area of monitoring new trends in the drug phenomenon, 
the EMCDDA made progress on the trendspotter 
methodology, wastewater-based epidemiology and the 
development of hospital emergencies data.
  The Best practice portal was revamped to become even 
more practice oriented. 
  The Management Board welcomed the first measures 
for the implementation of the agency’s first long-term 
strategy, the EMCDDA Strategy 2025. These implied the 
refinement and implementation of the new organisational 
structure and the alignment of the EMCDDA PD with the 
Strategy. 
  The agency continued its efforts to further improve its 
operational efficiency, and achieved an outstanding 
budget execution rate (100 % for commitment 
appropriations) at the end of the year.
In conclusion, the Management Board welcomes the 2017 
General Report of Activities, which provides an excellent 
overview of the agency’s achievements as set out in the work 
programme adopted by the Board.
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 CHAPTER 2
  Management
I  Management Board — main decisions
As usual the Management Board met twice during the year. 
The first meeting took place on 29-30 June and the second on 
14-15 December 2017.
At the June meeting, the Director presented the highlights of 
the EMCDDA’s budgetary and financial performance, as well 
as the main achievements of the EMCDDA in 2016 based on 
the General Report of Activities. The Management Board gave 
a favourable opinion on the EMCDDA’s final annual accounts 
for 2016 and congratulated the Director and his staff on the 
excellent level of budgetary execution. On the basis of the 
recommendation of the Budget Committee and the Executive 
Committee, the Management Board adopted amending 
budget no 1 to the 2017 EMCDDA budget. 
The Management Board took note of and agreed with the 
Working Arrangements between the EMCDDA and the Federal 
Office of Public Health of Switzerland, and mandated the 
Director to sign the Working Arrangements.
The Management Board agreed that Ms Elena Hedoux may 
attend the meetings of the EMCDDA Management Board as 
alternate observer of the Pompidou Group of the Council of 
Europe, in case of non-attendance of the designated observer 
of the Pompidou Group.
The meeting included an exchange of views about the 
challenges and perspectives posed by NPS in Europe. After a 
presentation by the European Commission on the situation 
concerning the new EU legislation on NPS, and a presentation 
by the EMCDDA, the Chair invited some Member States  
to briefly present innovative models in different areas related 
to NPS.
The Director updated the Management Board on the 
implementation of the Strategy 2025, in particular about 
the changes in the organisational design and the staff 
management.
At its 56th meeting, on 14-15 December 2017, the 
Management Board had a first discussion on the next external 
evaluation of the EMCDDA, which will be run by the European 
Commission (DG Migration and Home Affairs) in 2018 with the 
support of an external contractor. The European Commission 
presented the scope of the evaluation, which will be both to 
assess the relevance, effectiveness, efficiency, coherence and 
EU added value of the agency’s performance since 2013, and 
to propose concrete and useful recommendations which may 
lead to the revision of the agency’s mandate, should this be 
deemed necessary to allow the agency to better respond to 
the challenges posed by a constantly changing environment. 
The Chair invited some Member States to briefly present 
their experiences in linking national drug policies with data 
collection, monitoring and analysis. The aim was to explain 
why the drug policy or strategy has evolved in the country, for 
example to include licit and illicit substances, and how the 
respective NFP accompanied this evolution at the level of the 
data collection and methodology. The Chair and the Vice-Chair 
will represent the Management Board in the ad hoc group for 
the external evaluation.
The Board adopted some adjustments to the organisational 
structure and chart of the EMCDDA to support the 
implementation of the Strategy and ensure delivery of the 
expected results.
In line with the provisions of Article 32 of the Framework 
Financial Regulation applicable to EU agencies and of 
the EMCDDA Financial Regulation, the Management 
Board adopted the EMCDDA’s PD for the period 2018-20, 
including the 2018 work programme, on which the European 
Commission and the EMCDDA Scientific Committee had 
given a favourable opinion. The Board also adopted the 
EMCDDA’s preliminary draft PD for 2019-21, which includes 
the preliminary draft work programme for 2019. 
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As usual at the December meeting, the Management Board 
adopted the EMCDDA’s 2018 budget and preliminary draft 
budget for 2019. The budget for 2018 enters EUR 15 455 600 
as main revenue to be provided by the EU 2018 subsidy to the 
EMCDDA, EUR 412 932 for the contribution by Norway and 
EUR 276 550 for the contribution by Turkey for its participation 
in the work of the EMCDDA. The preliminary draft budget for 
2019 enters EUR 15 596 600 as main revenue to be provided 
by the EU 2019 subsidy to the EMCDDA, EUR 417 618 for the 
contribution by Norway and EUR 279 254 for the contribution 
by Turkey for its participation in the work of the EMCDDA. 
The Management Board took note of the Reitox Development 
Framework, defining the operating framework and main 
priorities for the Reitox network of NFPs to fulfil its roles 
and functions in the future, and adopted a new EMCDDA 
International Cooperation Framework.
Mr Xavier Poos (Luxembourg) was elected as member of the 
Executive Committee from 1 January 2018 to 31 December 
2020. 
The Management Board further endorsed the EMCDDA Action 
Plan further to the Internal Audit Service’s 2017 final audit 
report on ‘Management of data collection, validation and 
quality assurance in the EMCDDA’, and adopted a revised 
internal control framework for the EMCDDA.
Finally, the Director summarised the main results of the end-
term monitoring report on the implementation of the EMCDDA 
Strategy and work programme 2013-15. The Management 
Board welcomed the document as a crucial element for the 
upcoming external evaluation of the agency.
I  Executive Committee —  main decisions
In 2017, the Executive Committee met four times in Lisbon  
(12 May, 29 June, 20 October and 13 December).
At its meetings of 12 May and 29 June 2017, the Executive 
Committee reviewed the items of the draft agenda of the 
Management Board meeting of 29 to 30 June 2017, and 
proposed some modifications to draft documents. It was 
decided to test the feasibility of videoconferencing for future 
Executive Committee meetings in September.
On 20 October, the Executive Committee prepared for the 
Management Board meeting of 14 to 15 December 2017. On 
the basis of the recommendation of the Budget Committee, 
the Executive Committee agreed that the Chair should launch 
a written procedure for the adoption of amending budget No 2 
to the 2017 EMCDDA budget by the Management Board. 
In the light of the results of the videoconference test, it was 
decided that Executive Committee meetings will continue 
to take place at the EMCDDA premises in Lisbon, but that 
representatives of the European Commission could join the 
other members meeting in Lisbon by videoconference from 
Brussels if needed.
The Executive Committee passed in review on 13 December 
the items of the draft agenda of the Management Board 
meeting of 14-15 December 2017. The Executive Committee 
appointed Dr Fabrizio Faggiano as a member of the EMCDDA 
Scientific Committee from the reserve list until the end of 
the current mandate (December 2019), replacing Prof. Brice 
de Ruyver, who had sadly passed away on 19 October 2017. 
The Executive Committee also adopted, on behalf of the 
Management Board, general provisions for giving effect to the 
Staff Regulations on telework.
At the beginning of each meeting of the Executive 
Committee, the Chair of the Budget Committee reported on 
the conclusions of the meetings held prior to the Executive 
Committee meetings, and the recommendations made by the 
Budget Committee.
I  Budgetary and financial management
I Information in the report on budgetary and  financial management (Article 93 of the  Framework Financial Regulation)
Information on budgetary and financial management is 
covered by the report included in the EMCDDA’s Annual 
accounts 2017. 
In terms of procurement execution, the procurement plan was 
put in place, in line with the EMCDDA 2017 management plan, 
and successfully executed in close collaboration with all units.
The negotiated procedures launched during the course of the 
year are outlined in Table 7.
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TAbLE 6. EMCDDA tenders in 2017
Tendering 2017 figures Number of  direct contracts
Number of 
framework contracts
Negotiated procedures — disp. Article 134 — Rules of implementation 
of the Financial Regulation (exceptional procedures)
0 0 0
Negotiated procedure — single tender (1) 129 129 0
Negotiated procedure — at least three candidates 9 7 2
Negotiated procedure — at least five candidates 5 4 1
Open procedures 4 3 1
European Commission frameworks joined 5 0 5
I Summary information on budgetary operations   for 2017 in terms of budget operations, revenue  and expenditure
The information about the appropriations transferred in 
2017 can be found in the report on budgetary and financial 
management, as included in the EMCDDA Annual accounts 
2017. The EMCDDA Management Board approved two 
amending budgets in 2017, which were duly published.
In 2017, the EMCDDA received 100 % of the revenues 
envisaged in its 2017 budget. In this context, the agency 
once more achieved an outstanding performance in terms 
of execution of budget expenditure for its core budget: the 
theoretical maximum of 100 % was achieved for the second 
consecutive year. This re-confirmed and revealed the excellent 
administrative capacity and huge potential for budget 
management in the Centre.
The other main financial/performance indicators are 94.7 % 
for payment appropriations; 95 % for appropriations carried 
forward from 2016; and 1.2 % for cancelled/non-used payment 
appropriations.
I  Human resources management
I Human resources developments
The work to align the EMCDDA human resources processes 
and policies with the reform of the EU staff regulations 
continued in 2017. This included, in particular, the adoption 
of implementing rules on telework (DEC/MB/17/07). As 
in previous years, the EMCDDA played an active role in 
discussions held by several inter-agency working groups in this 
area.
(1) Including appointment letters and very low-value contracts.
TAbLE 7. EMCDDA negotiated procedures in 2017
Works Supplies Services Total for 2017
Number 
of 
contracts
Volume of 
contracts 
(EUR)
Number 
of 
contracts
Volume of 
contracts 
(EUR)
Number 
of 
contracts
Volume of 
contracts 
(EUR)
Number 
of 
contracts
%
Volume of 
contracts 
(EUR)
%
> 1 000 and  
≤ 15 000 EUR
12 34 434 15 64 897 72 449 042 99 88 548 373 40,57
> 15 000 and  
≤ 60 000 EUR
0 0 1 45 000 8 257 978 9 8 302 978 22,41
> 60 000 and  
≤ 135 000 EUR
0 0 0 0 5 500 389 5 4 500 389 37,02
Total 12 34 434 16 109 897 85 1 207 409 113 100 1 351 740 100
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No major changes occurred in the EMCDDA 2017 
establishment plan, apart from the reduction in the number of 
authorised posts by one compared with 2016, as requested 
by the European Commission and adopted by the EU budget 
authority.
I Brief description of the results of the screening/  benchmarking exercise
The results of the EMCDDA 2017 staff screening exercise 
reflect the EMCDDA’s efforts to ensure the effective and 
efficient allocation and use of its resources. The results show 
that 72.68 % of the EMCDDA’s human resources capacity was 
devoted to operational activities in 2017 and only 17.72 % 
was allocated to administrative support and coordination; 
the remaining 9.61 % was assigned to operations considered 
neutral (see Annex 2).
I Assessment by management
The EMCDDA has set its internal procedures for budget 
execution and internal control, while defining and 
implementing a partially decentralised management model, 
in accordance with the EMCDDA Financial Regulation, which 
integrally transposes the text of European Commission 
Delegated Regulation (EU) No 1271/2013 on the Framework 
Financial Regulation for EU agencies.
As a consequence, both the operational and financial 
decisions required for the implementation of the EMCDDA’s 
work programme and budget have been delegated to the 
Heads of unit. The Administration unit provides support to 
managers for budgetary and financial management execution 
and implementation of financial transactions, as well as for 
internal planning, monitoring and reporting.
These procedures have been codified and all of the EMCDDA’s 
deputy authorising officers have received specific training and 
information on their roles, duties and liabilities, in accordance 
with the provisions of financial and staff regulations.
The key actors and steps of the EMCDDA procedures for 
budget execution can be summarised as follows:
  Project manager: initiates and provides operational input 
for the administrative and financial operations related to 
project implementation (e.g. technical specifications for 
procurement procedures, cost estimates and ‘certified 
correct’ for payments).
  Financial management team: financial and contractual 
support officers provide assistance in the preparation of 
administrative and contract documents with the input of 
the project manager involved.
  Budget planning and monitoring: checks for consistency 
with work programme and budget allocations.
  Financial management: initiating officers carry out 
operations using the EMCDDA’s electronic management 
and accounting system (ABAC), prior to decisions of the 
Authorising Officer.
  Executive office unit: the verifying officer carries out ex 
ante financial checks. 
  Head of unit or Scientific Director: gives authorisation 
for budgetary and legal operations, and acts as deputy 
authorising officer by delegation (by the Director as 
EMCDDA Authorising Officer) for the execution of the 
tasks/activities of his/her unit, within the limits of the 
adopted EMCDDA annual work programme and budget.
  Accounting officer: executes and records payments and 
recovery orders.
The procedures presented above are consistent with the 
EMCDDA’s project-based working methods, which aim to 
integrate activity and resource management, in accordance 
with activity-based management/activity-based budgeting 
principles. In this context, the EMCDDA established 
procedures for planning, monitoring and reporting, with a 
clear indication of the actors involved, their roles and their 
responsibilities.
After the adoption of the new ‘Operating framework for the 
Reitox system’ in January 2003, a new grant agreement model 
was introduced for the annual co-financing of activities by the 
Reitox NFPs. This agreement requires that an external audit 
is carried out each year by an independent body or expert, 
in order to certify that any financial documents submitted 
to the EMCDDA comply with the financial provisions of the 
agreement, that the costs declared are the actual costs and 
that all receipts have been declared.
The EMCDDA’s activities and operations are scrutinised by 
several processes and actors:
  external audits by the European Court of Auditors  
(twice a year);
  external audits for specific projects (IPA-funded projects 
etc.);
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  discharges by the European Parliament (once a year);
  internal audits by the Internal Audit Service of the 
European Commission (IAS) (once a year);
  opinions of the European Commission’s services on the 
agency’s Programming Document (PD) (once a year);
  external periodical evaluations (set as every six years in 
the EMCDDA Founding Regulation);
  agreements by the European Commission on 
implementing rules for staff regulations (one agreement 
for each rule);
  consent by the European Commission on the possible 
deviation of the EMCDDA Financial Regulation from the 
European Commission’s Framework Financial Regulation 
for decentralised agencies;
  the European Data Protection Supervisor for compliance 
with Regulation 45/2001 (by prior notification and upon 
complaint);
  the European Anti-Fraud Office (upon complaint);
  the Ombudsman (upon complaint);
  the European Court of Justice (upon complaint).
Ex ante controls of financial transactions were applied 
exhaustively throughout 2017 to verify their compliance with 
the EMCDDA Financial Regulation and the corresponding 
implementing rules. These controls were carried out swiftly 
in order to ensure that payment deadlines were met, legal 
commitments were concluded in a timely manner and income 
was recovered promptly, without prejudice to the application of 
corrections, if required.
Financial workflows were properly defined and a sound system 
of authorisation of access to the ABAC system was put in 
place. The manual of procedures was applied and updated,  
as required.
TAbLE 8. Key features of the EMCDDA’s partially 
decentralised management mode
Level of operations  
(and actors) Role/operations
Decentralised level 
(operational and 
technical units)
Operational initiative/input and operational 
and financial decisions by delegation in 
order to implement the work programme 
and budget
Central level 
(Executive office unit 
and Administration 
unit)
Coordination and management 
of executive planning, monitoring, 
reporting and assessment of the 
implementation of the work programme 
and budget. Administrative and financial 
support, management and control of 
implementation
TAbLE 9. Key features of the EMCDDA’s partially decentralised management mode
Level of operations Actors Role/operations
Decentralised level 
(operational and 
technical units)
Project manager and Head of 
the unit concerned
Initiates and provides operational input to the operations required  
to implement projects
Central level 
(Administration unit)
budget planning and 
monitoring team
Checks the consistency of operations with the adopted work programme and 
budget. budgetary appropriations to be committed are set aside
Human resources 
management team
Defines rights and checks compliance with staff regulations for staff-related 
management and expenditure 
Financial management team
Prepares the required administrative and legal supporting documents and 
controls compliance with applicable regulations. Processes the required financial 
operations
Central level  
(Executive office unit)
Verifying officer Ex ante verification
Decentralised level 
(operational and 
technical units)
Head of unit/deputy 
authorising officer 
Authorises budgetary and legal commitments and payments
Central level 
(Administration unit)
Accounting officer Executes and records payments and recovery orders
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I Assessment of audit results during 2017   and the follow-up of audit plans, audits  and recommendations
In 2017, following up on observations and recommendations 
expressed by the ECA, the EU Budget Authority and the IAS, 
the EMCDDA implemented measures to further improve its 
management and internal control systems, as outlined below.
I Internal Audit Service
One of the three components contained in recommendation 
4 arising from the 2013 IAS audit on ‘Budget and Monitoring’, 
and rated by the internal auditors as ‘important’, has not yet 
been fully implemented. This recommendation concerned 
the non-availability in the Agency at that time of a continuous, 
coherent and reliable information on the achievement of 
planned results and the fact that the ABB system as a 
management tool might be rendered ineffective. The EMCDDA 
has in the meantime made significant progress in performance 
monitoring, namely by introducing, since 2016, a detailed 
internal management plan, which articulates the operational 
and budgetary planning. Furthermore, for each expected 
output/result in the work programme, a clear overview has 
been provided, identifying the milestones and timeline for 
implementation, budget and responsible actors. However, 
the management information system (MIS) for performance 
monitoring of the agency is not yet in place, the delay being 
due to the lack of human and financial resources, as well 
as to the need to articulate the tool with the new project 
management methodology. It is expected that the monitoring 
tool will be piloted by the end of 2018 and its gradual 
implementation will begin in 2019.
Clear progress has been made regarding implementation of 
certain recommendations arising from the 2015 IAS audit on 
information technology (IT) project management:
  Two out of the three recommendations relating to the 
alignment of IT tools with business needs have been 
implemented; the remaining one, namely the setting up 
of an enterprise architecture management framework, is 
nearly implemented. 
  The adoption of an IT project management methodology 
was achieved in 2017 (its implementation is expected by 
mid-2018).  
In January 2017, the IAS presented its final report on the 2016 
Limited Review on Business Continuity in the EMCDDA.  
This report yielded three important recommendations, 
summarised below: 
Recommendation No 1: the agency should develop an 
appropriate methodology for performing its business impact 
analysis. It should include the risks against which functions 
are assessed in case of interruptions and guidance on their 
quantitative assessment. Based on such methodology, 
it should, inter alia, identify its business functions. This 
assessment should be aimed at identifying the business 
consequences of a prolonged interruption of a function in 
worst-case scenarios. 
Recommendation No 2: the agency should ensure that all staff 
supporting its key activities or who are part of the business 
continuity group and/or of the incident response team 
receive effective and regular training on business continuity 
management. Moreover, an evaluation of the need to provide 
training and awareness-raising sessions on business 
continuity to the entire staff ought to be performed.
Recommendation No 3: the agency should update its list 
of critical records by also including critical paper records. 
Moreover, it should distinguish the records according to their 
physical location and whether they are hard or soft copies; 
for critical paper records, the locations of the original and of 
any copies should be indicated, in order to cope if the primary 
location is destroyed. Finally, in order to ensure that the 
implementation of the above actions is sustained, the agency 
should appoint a person responsible for ensuring that the 
critical records are safeguarded and their location is known.
All the recommendations above were implemented on time  
in 2017. 
In November 2017, the IAS issued its final report concerning 
the 2017 audit, which focused on ‘Management of Data 
Collection, Validation and Quality Assurance in the EMCDDA’. 
This report yielded two recommendations, whose content is 
summarised below:
Recommendation No 1 (ranked as ‘Very Important’): the 
EMCDDA should perform a comprehensive business needs 
analysis aimed at identifying current and emerging needs and 
the related IT functionalities to support the data collection, 
validation and quality assurance processes. Special attention 
should be paid to potential new requirements pending the 
adoption of the new Regulation of the Centre; the result of this 
exercise should serve as the basis for a gap analysis between 
requirements identified and the functionalities of current tools: 
it will help identify future IT solutions that could maximise the 
efficiency of the data collection and quality assurance process, 
pursuing a sound balance between investing in new solutions 
and building upon current strengths.
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Recommendation No 2 (ranked as ‘Important’): the EMCDDA 
should review and improve its data quality management 
framework by ensuring the alignment of the document with the 
EMCDDA Strategy 2025 and the 2017-19 SPD. Moreover, the 
framework ought to be completed with a number of elements 
such as a better definition of quality goals and implementation 
priorities (for instance methods for dissemination of data 
quality requirements to EMCDDA partners, a clearer definition 
of roles and responsibilities of all actors involved in data quality 
management, and distinguishing tools already available from 
those under development).
Following reception of this Audit Report, a suitable action plan, 
aimed at dealing with the recommendations received, was 
prepared, submitted to and endorsed at the December 2017 
Management Board meeting. 
I European Court of Auditors
Pursuant to the recommendation to improve the monitoring 
of the execution of framework contracts within the limit of the 
established ceiling, the EMCDDA has put in place a specific 
procedure to improve the central planning and monitoring of 
its procurements, including for framework contracts.
Furthermore the EMCDDA has adjusted its decision on the 
delegation of the Authorising Officer’s powers in order to set 
out more explicitly the acts covered by this delegation, with 
special attention to framework contracts.
I Follow-up on observations from the  discharge authority
I Measures taken in light of the observations and  comments that accompanied the decision on   discharge for 2015
Observation No 9 of EP discharge decision
Notes that the IAS carried out an audit on ‘IT project 
management’ in the Centre and it yielded six main 
recommendations which covered issues on Business-IT 
alignment, IT project management, and requirements for 
management and systems development; notes furthermore 
that the Centre established a suitable action plan which 
was endorsed by its Management Board, and that the 
recommendations were to be followed in substance by the 
Centre; calls on the Centre to report to the discharge authority 
upon the implementation of the action plan;
Measures taken by the EMCDDA
Clear progress has been made regarding the implementation 
of recommendations 1.1 and 1.2, whose deadline was 
nevertheless extended to the end of 2017. Recommendation 
1.1 was implemented by the end of 2017. Recommendation 
1.3 was implemented before the deadline (end of June 2017) 
originally established in the action plan.
Good progress has also been made as regards implementation 
of recommendations 2.1 and 2.2. Because of the technical 
complexity of some components of the IT project management 
methodology and processes, as well as stringent financial 
and human resources constraints, the deadlines initially set 
needed to be postponed for periods ranging from six to 18 
months.
Implementation of recommendations 3.1 and 3.2 is ongoing. 
The respective deadlines have however been extended to the 
end of 2018. 
Observation No 14 of EP discharge decision
Highlights the success of the Centre in its different missions; 
welcomes the new strategy and work programme for the 
period 2016-2018; encourages, however, the development 
and implementation of a much longer-term strategy as 
committed to by its Director;
Measures taken by the EMCDDA
The EMCDDA has now in place a new, long-term, strategy: 
Strategy 2025. The document was adopted by the 
Management Board in December 2016 and is now being 
used to guide the work of the agency and it is the basis for the 
EMCDDA PDs.
Observation No 15 of EP discharge decision
Emphasises the important role of the Centre in detecting 
new trends, assessing threats posed by drugs to the health 
and security of young Europeans and developing prevention 
strategies; welcomes the notification of 98 new psychoactive 
substances; encourages sustained efforts to monitor the use 
of the internet as a vehicle for drug supply;
Measures taken by the EMCDDA
The EMCDDA has been implementing some innovative 
projects, which aim to use the internet as a source of data for 
our drug monitoring. This includes OSI for both surface web 
and deep web (darknet markets). These projects are under way, 
with plans to implement a framework for systematic darknet 
monitoring by 2020.
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Furthermore, an in-depth publication on the internet and 
drugs was released in 2016: ‘The internet and drug markets’ 
Insights). Moreover, the internet and cybercrime were one of 
the priorities of the JHA agencies network in 2017 (chaired by 
the EMCDDA in that year) and a conference on ‘The expanding 
influence of the internet, the exploitation of cyberspace 
and the transformational nature of new technologies’ was 
organised by the EMCDDA in April 2017 as chair of the 
network. Under the same auspices, on 28 November the 
joint EMCDDA-Europol publication ‘Drugs and the darknet: 
perspectives for enforcement, research and policy’ was 
launched in Lisbon, in the presence of the two Directors and 
the EU Commissioner for Home Affairs on 28 November.
Observation No 16 of EP discharge decision
Acknowledges the fact that the Centre released 45 
publications, contributed its expertise to around 300 key 
external scientific and institutional events and that its 
staff contributed to 27 scientific articles; encourages the 
dissemination of results through social media and online tools;
Measures taken by the EMCDDA
Social and multimedia channels are being increasingly used 
for giving information on EMCDDA activities and results. 
Circulation alerts and analyses are going to be produced for 
specific customer groups.
Online communication remains the agency’s preferred 
channel for disseminating up-to-date knowledge on all facets 
of the drugs problem, with the EMCDDA’s website at its 
core. Ongoing website developments continue to offer the 
EMCDDA’s audiences access to new interactive products 
and tools and more multilingual elements. The website is 
regularly updated and developed. Online top-level overviews 
and updates on emerging issues are published for all the 
substantive areas. Furthermore, the EMCDDA provides 
improved access to its data to interested third parties. 
The agency produces focused online analyses, thematic 
outputs on topical developments and emerging issues, and 
updates, in all areas. The ‘Policy alerts system’, which was 
launched in 2016, is maintained; as part of this system, the 
agency continues to monitor news alerts related to policy-
relevant cannabis topics (legislation in Europe, models of 
supply, coordinating offices in third countries, evaluations of 
implemented systems), analyse them and produce targeted 
messages and brief objective summaries for the group of 
key policymakers who have subscribed to the system. The 
EMCDDA also maintains the public web page with key 
outlines of EU and third country cannabis policies, hosting the 
summaries and links.
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 CHAPTER 3
 External evaluation
In line with Article 23 of the EMCDDA Founding Regulation 
recast, the European Commission shall initiate an external 
evaluation of the agency every six years and forward the 
evaluation report to the European Parliament, the Council and 
the Management Board of the EMCDDA.
The last external evaluation of the agency was completed in 
June 2012.
The final report contained 15 recommendations and the 
agency prepared an action plan to implement them. This action 
plan was adopted by the Management Board at its meeting of 
5-6 July 2012.
With a view to monitoring the implementation of the follow-up 
action plan, an annual internal assessment exercise was put in 
place and the results were presented in the General Reports of 
Activities for 2013 and 2014.
All the actions which were under the control of the EMCDDA 
had been implemented by the end of 2014. On this ground, a 
decision was adopted by the Management Board in September 
2015 to consequently close all these recommendations.
The fourth external evaluation of the EMCDDA will be carried 
out by the European Commission during 2018. The exercise 
will evaluate the success of the implementation of the three-
year strategy and work programme for 2016-18, as well as 
of the previous strategy and work programme for 2013-15. It 
is planned that the draft Final report will be presented to the 
EMCDDA Management Board in December 2018, further to 
which a follow-up action plan will be developed by the agency 
in 2019. 
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 CHAPTER 4
  Assessment of the effectiveness of the 
internal control systems
I  Risk management and compliance with, and effectiveness of, the internal control standards
As in previous years, a comprehensive risk identification and 
assessment exercise aimed at improving risk management in 
the EMCDDA was carried out in 2017. The central risk register 
was regularly updated. Risk analysis was a continuous exercise 
at the EMCDDA during the year, although, at the stage of 
preparation of annual work programmes, more systematic 
analyses were conducted by managers.
A comprehensive document that reviews and lays down 
the progress made in the implementation of the EMCDDA’s 
Internal Control Standards (ICS) was drawn up in early 2013, 
and has been updated regularly since then. As a result of 
these reviews, two main areas in which implementation 
of the EMCDDA’s ICS should be improved have been 
identified, namely (in order of priority) ‘Business continuity’ 
(ICS 10) and ‘Governance in IT’, notably regarding ‘Projects’ 
management’ (one key feature under ICS 7 — ‘Operational 
structures’). The EMCDDA adopted in 2017 further measures 
aimed at mitigating residual risks, taking stock also from 
the recommendations issued in these fields by the IAS. In 
December 2017, the EMCDDA Management Board formally 
adopted a new internal control framework, which will be 
applied from 2018 onwards. 
The adoption, in September 2013, of a fully fledged Business 
continuity plan (BCP) for the agency as a whole reflected 
a major step in the implementation of the aforementioned 
ICS. Improvements entered in 2017 allowed the document to 
become detailed and comprehensive enough to enable the 
EMCDDA to act swiftly and operate recoveries in the event of 
an emergency or disaster. 
It is also worth mentioning the continuous effort made in 
relation to governance and technical management of ICT 
operations. In this area, business continuity was achieved 
without major incidents, namely by ensuring sound 
procurement procedures, adequate licensing and proper 
testing of applications. Furthermore, as in previous years, 
additional actions were taken throughout 2017 (notably, 
regarding the adoption of a new project management 
methodology), in order to further reduce the residual risk 
levels remaining in the management of some ICT-related 
investments and projects.
In combination with the IT sector risk register, an adequate 
risk management plan was set up. This plan identifies, for 
each area, the estimated risk level, the additional controls that 
should be put in place and the list of the ongoing programmes 
and projects that will contribute to the reduction of the 
outstanding residual risks. As mentioned in the ‘Assessment 
of audit results’ section above, the IAS carried out an audit on 
‘IT project management in the EMCDDA’ as well as a limited 
review on business continuity, in September 2015 and 2016, 
respectively. The implementation of a number of the respective 
recommendations has already allowed the agency to make 
further improvements in the areas concerned, notably by 
better alignment of IT projects with core business needs and 
an enhanced capacity to deal with events of emergency or 
disaster.
The monitoring of performance supported by key performance 
indicators (KPIs) (ICS 5) was further consolidated throughout 
2017, building on the achievements of previous years. This was 
the third year in which KPIs were in place for all the main areas 
of work in the annual work programme; with support from an 
external consultant, the agency has continued developing 
the necessary data collection and reporting mechanisms, 
piloted some of the new measurement tools, refined working 
definitions and developed the internal monitoring and 
evaluation plan. The KPIs will require further improvement and 
alignment with the EMCDDA Strategy 2025.
Moreover, the agency has been working on the development of 
an IT tool to integrate the planning and monitoring of activities 
(MIS). However, the progress achieved has been slower than 
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originally planned because of (1) the need to prioritise work on 
the PD (top-level priority) from the perspective of the business 
owner (the planning function) and (2) development needs of 
other level 1 priority projects from the perspective of the ICT 
team, notably relating to project management automation 
processes. The deadline for the entering into production of 
this platform is currently the end of 2018, though achievement 
of this goal still hinges on the availability of the necessary 
resources (both human resources and funding).
Internal EMCDDA coordination mechanisms (e.g. the Heads 
of unit meetings, Editorial board meetings, ICT Steering 
Committee meetings and the Scientific coordination meetings) 
contributed to strengthening risk management processes, 
by enhancing the capacity of managers and other key staff 
to closely monitor all major issues related to the timely and 
effective implementation of planned activities, the delivery of 
outputs and the achievement of results.
The risks more directly associated with operational activities, 
particularly the lack of proper funding for the Reitox 
NFPs, which have been apparent since 2014, once again 
materialised, rising to levels that have become more serious 
since 2015. In particular, funding cuts made by national 
authorities to some NFPs’ budgets in the last quarter of 2016, 
since maintained in 2017, may imply corresponding reductions 
in co-funding provided by the EMCDDA; this event would 
trigger further negative consequences for the capabilities 
of the NFPs with regard to complying with their reporting 
obligations. In addition, these difficulties were compounded 
by lingering budget constraints faced by the EMCDDA itself, 
which have led to decreases in the amounts granted to NFPs 
for properly complying with their reporting obligations to the 
agency.
As a consequence of these events, the rationalisation of the 
present NFP reporting package had to be carried out and 
should continue; this involves, notably, regular reviews of 
the availability of core data needs, on the basis of properly 
defined priorities; feedback to the NFPs on their performance 
in respect of availability of core data and reporting obligations 
towards the EMCDDA; and enhancement of coordination and 
performance monitoring.
Furthermore, reductions in the reporting capacities of Member 
States, already evident in 2015, persisted in 2016 and 2017. 
As a first consequence, timeliness and comprehensiveness 
of reporting by Member States on new threats and drug 
developments have been affected; moreover, some 
comparative data became unavailable, which curtailed the 
possibility of carrying out useful analyses at European level. 
Following the materialisation of this risk, a closer monitoring 
of and feedback to the Member States on their reporting 
performance was envisaged and is currently ongoing. Closer 
attention ought to be paid to reporting biases and statistical 
approaches; these measures should allow corrective action to 
be taken by Member States.
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 CHAPTER 4
  Management assurance
I  Declaration of assurance by the Authorising Officer
I, the undersigned, Director of the European Monitoring Centre for Drugs and Drug Addiction
In my capacity as Authorising Officer
  Declare that the information contained in this report gives a true and fair view (4).
  State that I have reasonable assurance that the resources assigned to the activities 
described in this report have been used for their intended purpose and in accordance with 
the principles of sound financial management, and that the control procedures put in place 
give the necessary guarantees concerning the legality and regularity of the underlying 
transactions.
  This reasonable assurance is based on my own judgement and on the information at my 
disposal, such as the results of the self-assessment, the observations of the Internal Audit 
Service, the implementation of recommendations issued under ex post assessments and 
the lessons learnt from the reports of the Court of Auditors for years prior to the year of this 
declaration.
  Confirm that I am not aware of anything not reported here which could harm the interests 
of the institution.
Done in Lisbon on 18 May 2018
Alexis Goosdeel 
Director
 
(4) ‘True and fair’ in this context means a reliable, complete and correct view on the state of affairs in the service. 
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I  ANNEX 1 Organisational chart
Director
Alexis Goosdeel (DIR)
Unit
Public health
(HEA) 
Unit
Security 
(SAT)
Unit
Reitox and
external partners 
(RTX)
Unit
Communication
(COM)
Unit
Information and
communication
technology
(ICT)
Unit
Administration 
(ADM)
Sector
Support to policy
Sector
Analytical hub
Sector
Support to practice
Sector
Infrastructure and
logistics
Sector
Financial management
Sector
Human resources
management
Sector
Markets, crime and
supply reduction
Sector
International cooperation
Sector
Media relations
and marketing
Sector
ICT project
management
Sector
Action on new drugs
Executive oce (EXO) Data Protection Ocer (DPO)
Scientic division (SDI)
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I Breakdown of EMCDDA staff as of  31 December 2017 
Categories/Grade Officials
Gender Temporary 
agent
Gender
Male Female Male Female
AD
15
14 1 1
13 1 1 3 2 1
12 3 3 4 3 1
11 7 3 4
10 2 1 1
9 2 2 6 3 3
8 11 3 8
7 5 3 2
6 1 1
5 2 2
Subtotal AD 6 6 0 42 21 21
AST
11
10 1 1
9 3 2 1
8 1 1
7 1 1 3 2 1
6 6 1 5
5 1 1 6 4 2
4 1 1
3
2 1 1
1
Subtotal AST 3 0 3 21 11 10
TOTAL 9 6 3 64 33 31
Function group
Gender
Male Female
CA
IV 4 1 3
III 9 3 6
II 13 1 12
I 3 3
TOTAL CA 29 8 21
AD: administrator; AST: assistant; CA: contract agent.
Total EMCDDA 
staff
Gender
Male Female
101 46 55
% 45.54 % 54.46 %
Seconded 
national expert
1 0
Annexes
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I Results of the 2017 benchmarking exercise
Job type (sub-)category % of staff
Administrative support and coordination 17.72
Administrative support 17.09
Coordination 0.63
Operational 72.68
Top level operational coordination 4.57
Programme management and 
implementation
56.61
Evaluation and impact assessment 0.00
General operational 11.50
Neutral 9.61
Finance/control 9.61
Linguistics 0.00
0 5 10 15 20 25 30 35
United Kingdom
Sweden
Finland
Slovakia
Slovenia
Romania
Portugal
Poland
Austria
Netherlands
Malta
Hungary
Luxembourg
Lithuania
Latvia
Cyprus
Italy
France
Spain
Greece
Ireland
Estonia
Germany
Denmark
Czech Republic
Croatia
Bulgaria
Belgium
Ocials (9) Temporary agents (63) Contract agents (29)
Function group 
and grade
Number of 
days
Function group 
and grade
Number of 
days 
AD5 11 AST9 0
AD6 7 AST10 0
AD7 37.5 AST11 0
AD8 52 GFI1 0
AD9 51 GFI2 0
AD10 11 GFI3 13.5
AD11 43 GFII4 1
AD12 8.5 GFII5 4.5
AD13 1 GFII6 17
AD14 0 GFII7 40
AD15 0 GFIII8 0
AD16 0 GFIII9 23.5
AST1 0 GFIII10 4
AST2 0 GFIII11 13
AST3 0 GFIII12 1
AST4 0.5 GFIV13 0
AST5 42 GFIV14 7.5
AST6 27 GFIV15 0
AST7 30.5 GFIV16 0
AST8 13.5 GFIV17 7
Total: 467.5
I Staff by nationality
I Number of days of leave authorised under   the flexitime and compensatory leave schemes 
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I  ANNEX 3 Implementation of the 2017 work programme by objectives and  expected outputs/results
This annex presents in detail the activities contained within the work programme for 2017 and 
how they were carried out during the course of the year. It is available online. 
I  ANNEX 4 Key performance indicators 
This annex is available online.
I  ANNEX 5 Key external events, conferences and meetings 
This annex is available online.
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I  ANNEX 6 Members of the EMCDDA’s statutory bodies
I Management Board
The Management Board consists of one representative from each Member State, two representatives of the European Commission, 
two independent experts who are particularly knowledgeable in the field of drugs, designated by the European Parliament, and 
one representative from each country thathas concluded an agreement with the EMCDDA (i.e. Norway and Turkey). Non-voting 
observers, such as those from international organisations with which the agency cooperates, may also be invited to Management 
Board meetings.
Country/organisation Member Substitute
Belgium Claude GILLARD Vladimir MARTENS
Bulgaria Plamen POPOV Momtchil VASSILEV
Czech Republic Jindrich VObOŘIL Lucia KISSOVA
Denmark Lars PETERSEN Sofie DENCKER
Germany Marlene MORTLER Jörg PIETSCH
Estonia Anna-Liisa PÄÄSUKENE Ain PEIL
Ireland Susan SCALLY brian DOWLING
Greece Christina DIAMANTOPOULOU Gerasimos PAPANASTASATOS
Spain Francisco bAbÍN VICH Maria Sofia ARAGÓN SÁNCHEZ
France Laura d’ARRIGO (Chair) Nicolas PRISSE
Croatia Željko PETKOVIĆ Sanja MIKULIĆ
Italy Maria CONTENTO Elisabetta SIMEONI
Cyprus Stelios SERGIDES Maria AFXENTIOU
Latvia Dzintars MOZGIS
Lithuania Inga JUOZAPAVIČIENÉ Gražina bELIAN 
Luxembourg Xavier POOS Alain ORIGER
Hungary Mónika SZÁSZIK Ibolya CSÁKÓ
Malta Richard MUSCAT Marilyn CLARK
Netherlands Victor SANNES
Austria Franz PIETSCH (Vice-Chair) Johanna SCHOPPER
Poland Piotr JAbŁOŃSKI bogusława bUKOWSKA
Portugal João GOULÃO Manuel CARDOSO
Romania Sorin OPREA Cătălin NEGOI-NIŢĂ
Slovenia Vesna-Kerstin PETRIČ Jože HREN
Slovakia boris bÁNOVSKÝ Eva DEbNÁROVÁ
Finland Elina KOTOVIRTA Kari PAASO
Sweden Henrik MELIN bo PETTERSON
United Kingdom Rosanna O’CONNOR Lauren COMbER
European Commission Olivier ONIDI and Luigi SORECA Floriana SIPALA and Wojciech KAŁAMARZ
European Parliament Wolfgang GÖTZ and Tomas ZAbRANSKY
Norwegian representatives Lilly Sofie OTTESEN Hege Christina bREDESEN
Turkish representatives İbrahim H. SEYDIOĞULLARI Murat SARIGÜZEL
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Observers
Scientific Committee Anne Line bRETTEVILLE-JENSEN
Reitox spokesperson Lies GREMEAUX
UNODC Gilberto GERRA
Council of Europe Pompidou Group Thomas KATTAU
WHO Lars MØLLER
I Executive Committee
The Management Board is assisted by an Executive Committee. The Executive Committee is made up 
of the Chair and the Vice-Chair of the Management Board, two other members of the Management 
Board representing the Member States and appointed by the Management Board, and two 
representatives of the European Commission. The Executive Committee prepares and follows up the 
decisions of the Management Board, and assists and advises the EMCDDA Director.
Laura d’ARRIGO France (Chair of the Management board)
Franz PIETSCH Austria (Vice-Chair of the Management board)
João GOULÃO Portugal
Susan SCALLY Ireland
Claude GILLARD belgium (Chair of the budget Committee, observer)
Two representatives of the European Commission
I Scientific Committee
The members of this Committee are selected for their independence and proven expertise  
in a particular field/speciality, as indicated below.
Field/speciality Scientific Committee Member(s)
Basic biological, neurobiological and behavioural research
Fernando RODRIGUEZ de FONSECA
Rainer SPANAGEL
Drug policy
Henri bERGERON
Anne Line bRETTEVILLE-JENSEN
Krzysztof KRAJEWSKI
Population-based research
Catherine COMISKEY
Paul DARGAN
Dirk J. KORF
Matthew HICKMAN
Supply, supply reduction
brice DE RUYVER
Letizia PAOLI
Demand reduction
Gerhard bÜHRINGER 
Marina DAVOLI
Gabriele FISCHER
Henk GARRETSEN
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I  ANNEX 7 Use of the available resources
Notes:
All amounts in this annex are given in EUR.
CA = contract agents; FTE/year = full-time equivalent per year; O = officials; TA = temporary agents; SNE = seconded national experts.
Appropriations for cost/expenditure for operational activities and staff directly involved in the implementation of the EMCDDA mission/task/WP.
Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that indirectly aim to implement the EMCDDA mission/task/WP, as their immediate aim is to support operational activities and 
staff. These overheads are distributed to operational activities in proportion to the human resources assigned for the implementation of these activities.
I A. Key areas (KAs)
WP action areas
Main actors for 
implementation/ 
cost objects
Assigned HR (FTE) Initial allocation of budget resources — non-assigned appropriation 
Final allocation of budget resources — 
non-assigned appropriation 
Executed budget — non-assigned 
appropriation
O TA CA SNE Total HR
Direct 
cost of 
operations
Indirect 
costs of 
operations
Total budget Direct cost of operations
Indirect 
costs of 
operations
Total budget Direct cost of operations
Indirect 
costs of 
operations
Total budget 
execution
KA 1: Communicating 
evidence and 
knowledge exchange
EPI, IbS, SAT, SDI, 
COM, RTX 1,75 16,75 4,50 0,00 23,00 2 400 531,78 1 504 220,78 3 904 752,56 2 400 531,78 1 504 220,78 3 904 752,56 2 400 531,78 1 504 220,78 3 904 752,56
KA 2: Early warning 
and threat assessment SAT, EPI, IbS, COM 0,00 5,00 3,00 0,00 8,00 956 229,41 384 238,75 1 340 468,16 960 909,78 384 238,75 1 345 148,53 960 909,78 384 238,75 1 345 148,53
KA 3: Situation, 
responses and trend 
analysis
EPI, IbS, SAT, SDI, 
COM 1,00 11,15 3,75 1,00 16,90 1 570 737,82 1 055 938,07 2 626 675,89 1 570 737,82 1 055 938,07 2 626 675,89 1 570 737,82 1 055 938,07 2 626 675,89
Total 2,75 32,90 11,25 1,00 47,90 4 927 499,01 2 944 397,60 7 871 896,61 4 932 179,38 2 944 397,60 7 876 576,98 4 932 179,38 2 944 397,60 7 876 576,98
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I B. Cross-cutting areas (CCAs)
WP action 
areas
Main actors for 
implementation/ 
cost objects
Assigned HR (FTE) Initial allocation of budget resources —  non-assigned appropriation 
Final allocation of budget resources —  
non-assigned appropriation 
Executed budget —  
non-assigned appropriation
O TA CA SNE Total HR
Direct cost of 
operations
Indirect costs 
of operations Total budget 
Direct cost of 
operations
Indirect costs 
of operations Total budget 
Direct cost of 
operations
Indirect costs 
of operations
Total budget 
execution
CCA A: 
Information 
collection and 
management
EPI, SAT, RTX 0,50 3,25 6,25 0,00 10,00 3 902 911,24 1 242 558,06 5 145 469,30 3 902 911,24 1 242 558,06 5 145 469,30 3 902 911,24 1 242 558,06 5 145 469,30
CCA b: 
Quality 
assurance
SDI, EPI, COM, RTX 1,25 5,00 1,65 0,00 7,90 845 493,77 521 365,67 1 366 859,44 845 493,77 521 365,67 1 366 859,44 845 493,77 521 365,67 1 366 859,44
CCA C: 
Cooperation 
with partners
RTX, SDI, DIR/EXO 1,30 1,85 0,75 0,00 3,90 426 379,97 295 688,29 722 068,26 426 379,97 295 688,29 722 068,26 426 379,97 295 688,29 722 068,26
Total 3,05 10,10 8,65 0,00 21,80 5 174 784,98 2 059 612,02 7 234 397,00 5 174 784,98 2 059 612,02 7 234 397,00 5 174 784,98 2 059 612,02 7 234 397,00
I C. Corporate area Governance
WP action 
areas
Main actors for 
implementation/ 
cost objects
Assigned HR (FTE) Initial allocation of budget resources —  non-assigned appropriation 
Final allocation of budget resources —  
non-assigned appropriation 
Executed budget — non-assigned 
appropriation
O TA CA SNE Total HR
Direct cost of 
operations
Indirect costs 
of operations Total budget 
Direct cost of 
operations
Indirect costs 
of operations Total budget 
Direct cost of 
operations
Indirect costs 
of operations
Total budget 
execution
CCA C: 
Cooperation 
with partners
RTX, SDI, DIR/EXO 1,30 1,85 0,75 0,00 3,90 426 379,97 295 688,29 722 068,26 426 379,97 295 688,29 722 068,26 426 379,97 295 688,29 722 068,26
Total 1,20 5,00 2,60 0,00 8,80 328 137,14 372 733,28 700 870,42 328 137,14 372 733,28 700 870,42 328 137,14 372 733,28 700 870,42
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I Grand total for operations (A, B, C)
Grand total for operations
Assigned HR (FTE) Initial allocation of budget resources —  non-assigned appropriation 
Final allocation of budget resources —  
non-assigned appropriation 
Executed budget —  
non-assigned appropriation
O TA CA SNE Total HR
Direct cost of 
operations
Indirect costs 
of operations Total budget 
Direct cost of 
operations
Indirect costs 
of operations Total budget 
Direct cost of 
operations
Indirect costs 
of operations
Total budget 
execution
7,00 48,00 22,50 1,00 78,50 10 430 421,13 5 376 742,90 15 807 164,03 10 435 101,50 5 376 742,90 15 811 844,40 10 435 101,50 5 376 742,90 15 811 844,40
I D. Support to operations — Corporate areas Administration and ICT
WP action areas Main actors for implementation/ cost objects
Assigned HR (FTE) Initial allocation of budget 
resources — non-assigned 
appropriation 
Final allocation of budget 
resources — non-assigned 
appropriation 
Executed budget — non-
assigned appropriation
O TA CA SNE Total HR
Administration: supporting core 
business
ADM (administration and 
resources/assets management)
3,00 11,00 8,00 0,00 22,00 4 144 325,38 4 144 325,38 4 144 325,38
Information and communication 
technologies 
ICT (equipment and services) 0,00 8,00 2,50 0,00 10,50 1 232 417,51 1 232 417,51 1 232 417,51
Total 3,00 19,00 10,50 0,00 32,50 5 376 742,89 5 376 742,89 5 376 742,89
I E. Summary of total allocations
WP action areas
Assigned HR (FTE)
Allocated budget resources — non-assigned appropriations
O TA CA SNE Total HR
For direct cost of operations (tables A + b + C) 7,00 48,00 22,50 1,00 78,50 10 435 101,50
For indirect cost of operations (i.e. direct costs of support activities — 
table D)
3,00 19,00 10,50 0,00 32,50 5 376 742,89
TOTAL 10,00 67,00 33,00 1,00 111,00 15 811 844,39
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I F.  Special projects
WP action areas
Main actors for 
implementation/ 
cost objects
Assigned HR (FTE) Budget — assigned appropriations
O TA CA SNE Total HR
Budget allocation — 
financing received in 
2017
Carried over and carried 
forward from 2016 Total available in 2017 Budget execution 2017
Preparation of IPA beneficiary 
countries for their participation 
in the EMCDDA (IPA 5 project — 
third year)
RTX 0,00 0,00 0,60 0,00 0,60 0,00 360 794,27 360 794,27 332 025,47
Preparation of IPA beneficiary 
countries for their participation in 
the EMCDDA (IPA 6 project — first 
year)
RTX 0,00 0,00 0,00 0,00 0,00 340 000,00 0,00 340 000,00 121 324,64
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I Economic outturn account
Economic outturn account 2017 2016 Variation
Contributions of EFTA countries belonging to the EEA 403 487,34 393 140,64 10 346,70
Recovery of expenses 16 953,19 30 308,61 -13 355,42
Revenues from  administrative operations 265 543,74 185 691,38 79 852,36
Other operating revenue 15 305 558,97 14 979 726,29 325 832,68
Total operating revenue 15 991 543,24 15 588 866,92 402 676,32
Administrative expenses -12 108 992,97 -11 661 760,08 -447 232,89
All staff expenses -9 512 006,18 -9 209 630,26 -302 375,92
Fixed asset related expenses -271 372,30 -271 968,95 596,65
Other administrative expenses -2 325 614,49 -2 180 160,87 -145 453,62
Operational expenses -4 458 218,17 -4 318 204,44 -140 013,73
Other operational expenses -4 458 218,17 -4 318 204,44 -140 013,73
Total operating expenses -16 567 211,14 -15 979 964,52 -587 246,62
Surplus/(deficit) from operating activities -575 667,90 -391 097,60 -184 570,30
Financial revenues 1 757,43 4 703,22 -2 945,79
Financial expenses -3 679,85 -3 628,04 -51,81
Surplus/(deficit) from non-operating activities -1 922,42 1 075,18 -2 997,60
Surplus/(deficit) from ordinary activities -577 590,32 -390 022,42 -187 567,90
Economic outturn for the year -577 590,32 -390 022,42 -187 567,90
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I EMCDDA 2017 budget appropriations and execution by nature of expenditure
Title Description EUR
1.
Expenditure relating to persons working with the EMCDDA  
Staff in active employment 9 709 412,15
Other staff-related expenditure (exchange of officials, etc.) 126 739,72
Total under Title 1 9 836 151,87
2.
Expenditure for support activities
Investment in immovable property, rental of buildings and associated costs 637 190,67
Data processing 758 771,08
Movable property and associated costs 104 979,89
Current administrative expenditure + postal charges and telecommunications 76 603,72
Socio-medical infrastructure 21 431,92
Total under Title 2 1 598 977,28
3.
Expenditure for operational activities
Statutory meetings 188 329,21
Expenditure on formal and other meetings + representatives' expenses 476 830,13
Studies, surveys, consultations 647 550,19
Publishing and translations 636 437,26
European Network on Drugs and Drug Addiction Reitox 2 134 341,38
Missions 293 227,08
Total under Title 3 — Section 1.01 4 376 715,25
Section 1.02 — Total core budget 15 811 844,40
Section 1.03
4.
Expenditure relating to other subsidies
EU financing of specific projects 
4a. IPA 5: financing for implementing pre-accession strategy 332 025,47
4b. IPA 6: financing for implementing pre-accession strategy 121 324,64
5. Other expenses (reserve) 0,00
Total budget 16 265 194,51
Notes:
The amounts committed under 4a, 4b and 4c contain the commitment appropriations, carried forward from the previous year.
Project IPA 6 is still ongoing.
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I Execution of the budget: credit consumption, 2017
Commitments
Title Description % consumption of available credits
1. Staff 100,0
2. Expenditure for support activities 100,0
3. Expenditure for operational activities 100,0
4a. Expenditure relating to IPA 5 92,0
4b. Expenditure relating to IPA 6 35,7
Total consumption of core budget (Titles 1, 2, 3 ) 100,0%
I Balance sheet: assets
Assets 31.12.2017 31.12.2016 Variation
A. Non-current assets
Intangible assets 397 171,18 395 117,08 2 054,10
Property, plant and equipment 344 666,32 417 564,76 -72 898,44
Plant and equipment 89 046,55 88 055,14 991,41
Computer hardware 190 551,28 244 679,50< -54 128,22
Furniture and vehicles 65 068,49 84 830,12 -19 761,63
Long term pre-financing 576 636,04 1 303 525,00 -726 888,96
Total non-current assets 1 318 473,54 2 116 206,84 -797 733,30
B. Current assets
Short-term pre-financing 726 888,96 740 908,00 -14 019,04
Short-term receivables 308 460,93 211 463,01 96 997,92
Current receivables 121 239,53 108 917,09 12 322,44
Other 187 221,40 102 545,92 84 675,48
Accrued income -2 920,55 0,00 -2 920,55
Deferred charges 190 141,95 102 545,92 87 596,03
Cash and cash equivalents 1 533 369,27 1 442 573,96 90 795,31
Total current assents 2 568 719,16 2 394 944,97 173 774,19
TOTAL 3 887 192,70 4 511 151,81 -623 959,11
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I Balance sheet: liabilities
Liabilities 31.12.2017 31.12.2016 Variation
Liabilities
Net assets 2 417 931,80 2 995 522,12 -577 590,32
Accumulated surplus/deficit 2 995 522,12 3 385 544,54 -390 022,42
Economic outturn for the year — profit+/loss- -577 590,32 -390 022,42 -187 567,90
Total net assets 2 417 931,80 2 995 522,12 -577 590,32
Current liabilities
Current liabilities — accounts payable
Current payables 6 007,66 4 159,49 1 848,17
Sundry payables 398,40 -1 212,88 1 611,28
Other 1 023 871,44 1 002 030,37 21 841,07
Accrued charges 1 014 038,15 986 897,77 27 140,38
Deferred income 9 833,29 15 132,60 -5 299,31
Accounts payable with consolidated EU entities 438 983,40 510 652,71 -71 669,31
Pre-financing received from consolidated EU entities 438 983,40 504 682,54 -65 699,14
Other accounts payable against consolidated EU entities 0,00 5 970,17 -5 970,17
Total current liabilities 1 469 260,90 1 515 629,69 -46 368,79
Total 3 887 192,70 4 511 151,81 -623 959,11
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I Budget outturn account for the financial year 2017
Budget outturn account 2017 2016
Revenue
balancing Commission subsidy + 15 135 600,00 14 794 000,00
Other subsidy from Commission (IPA 6) + 340 000,00 49 312,17
Fee income +
Other income (Norway contribution + Turkey contributuon + C4 Internal assigned revenues +  bank 
interests amending budget 1 & 2)
+ 693 197,96 638 152,46
TOTAL revenue (a) 16 168 797,96 15 481 464,63
Expenditure
Title I: Staff
Payments - 9 809 524,44 9 268 089,53
Appropriations carried over - 157 526,19 72 678,72
Title II: Administrative Expenses
Payments - 1 005 724,32 1 421 872,81
Appropriations carried over - 607 904,28 436 440,57
Title III: Operating Expenditure 
Payments - 4 555 075,39 4 400 485,69
Appropriations carried over - 203 511,55 338 973,65
TOTAL expenditure (b) 16 339 266,17 15 938 540,97
Outturn for the financial year (a-b) -170 468,21 -457 076,34
Cancellation of unused payment appropriations carried over from previous year (C8 title 1 & 2) + 18 245,88 18 278,73
Adjustment for carry-over from the previous year of appropriations available at 31.12 arising from 
assigned revenue
+ 380 860,06 675 419,35
Exchange differences for the year (gain +/loss -) +/- -271,84 2 602,23
The final ENPI budget balance was reimbursed to the EC on 30.11.2017 (project closed) 0,00 -13 810,85
Cancellation of unused payment appropriations  IPA 5 -28 768,80
Norway prorata 2017 -6 194,39 -6 992,04
Turkey prorata 2017 -3 638,90 -3 232,50
BALANCE OF THE OUTTURN ACCOUNT FOR THE FINANCIAL YEAR 189 763,80 215 188,58
balance year N-1 +/- 215 188,58 54 436,49
Positive balance from year N-1 reimbursed in year N to the Commission - -215 188,58 -54 436,49
Result used for determining amounts in general accounting 189 763,80 215 188,58
Commission subsidy — agency registers accrued revenue and Commission accrued expense 14 945 836,20
Pre-financing remaining open to be reimbursed by agency to Commission in year N+1 189 763,80
Not included in the budget outturn: 
Interest generated by 31/12/N on the Commission balancing subsidy funds and to be reimbursed to the Commission (liability) (+)
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About this report
The General Report of Activities is an annual publication providing a detailed progress 
report of the EMCDDA’s activities over a 12-month period. It catalogues the Centre’s 
achievements in each area of its annual work programme. The report is a useful information 
source for all those seeking comprehensive information on the Centre and its work.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction is the hub of drug-related 
information in Europe. Its mission is to provide the European Union and its Member States 
with ‘factual, objective, reliable and comparable information’ on drugs and drug addiction 
and their consequences. Established in 1993, it opened its doors in Lisbon in 1995,  
and is one of the European Union’s decentralised agencies. The Centre offers policymakers 
the evidence base they need for drawing up drug laws and strategies. It also helps 
professionals and researchers pinpoint best practice and new areas for analysis.
